Vitiligo treatment has changed significantly over recent years. For a long time, treatment discussions were often centred around topical creams, phototherapy, camouflage, and watchful waiting.<\/p>\n\n\n\n
These still matter, but the conversation has expanded. Today, dermatologists are also discussing immune pathways, targeted treatments, repigmentation goals, relapse prevention, patient-reported outcomes, and long-term treatment planning.<\/p>\n\n\n\n
EADV\u2019s own vitiligo task force brings together global experts and patient representatives to support collaboration, updated guidance, and clearer communication around emerging insights. This is important because vitiligo care cannot be shaped by laboratory research alone.<\/p>\n\n\n\n
It must also reflect what patients experience in real life. For example, a treatment may produce visible repigmentation in a clinical trial, but patients may still have concerns about treatment length, side effects, cost, clinic visits, or how much improvement is realistic. EADV sessions help connect these scientific and practical sides of care.<\/p>\n\n\n\n
They also allow clinicians to compare experiences across countries. Vitiligo can be managed differently depending on healthcare systems, access to phototherapy, medication availability, and local prescribing guidance. By discussing these differences openly, specialists can better understand where care is progressing and where gaps still remain.<\/p>\n\n\n\n
Understanding Vitiligo as an Immune-Mediated Condition<\/strong><\/h2>\n\n\n\nOne major theme in EADV vitiligo sessions is the evolving understanding of vitiligo itself. It is no longer viewed only as a cosmetic pigment issue, but as a complex condition involving immune system activity, genetic factors, oxidative stress, melanocyte damage, and environmental triggers.<\/p>\n\n\n\n
This shift in understanding matters because how a condition is defined directly influences how it is treated. If vitiligo is seen only as a loss of skin colour, treatment may focus mainly on repigmentation or cosmetic management. However, if it is understood as an immune-mediated condition, then treatment also needs to consider immune activity, inflammation, disease stability, and prevention of further spread.<\/p>\n\n\n\n
Recent dermatology research describes vitiligo as a chronic depigmenting disorder involving loss of melanocytes, with ongoing studies focusing on immune pathways and targeted therapies. This scientific progress is helping move treatment towards more mechanism-based and personalised approaches rather than one-size-fits-all care.<\/p>\n\n\n\n
At EADV sessions, this knowledge is translated into practical clinical questions such as whether the disease is active or stable, whether it is segmental or non-segmental, and whether new lesions are appearing. These considerations help dermatologists choose more appropriate and tailored treatment strategies for each patient.<\/p>\n\n\n\n
Diagnosis and Classification<\/strong><\/h2>\n\n\n\n![\"\"](\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-5-2-1024x559.jpg\")
<\/figure>\n\n\n\nVitiligo sessions at EADV often focus on how dermatologists assess and classify the condition. This is important because vitiligo is not the same in every person. The pattern, speed of change, and response to treatment can vary widely.<\/p>\n\n\n\n
Some people have small, stable patches that remain unchanged for long periods, while others experience more active disease with spreading depigmentation. The areas affected can also differ, with the face, hands, feet, and other body sites showing different behaviours and treatment responses.<\/p>\n\n\n\n
Segmental vitiligo behaves differently from non-segmental vitiligo, and this distinction plays a key role in planning treatment. EADV discussions also highlight the importance of assessing disease extent, progression, previous treatments, and impact on quality of life to guide realistic expectations and more personalised care.<\/p>\n\n\n\n
Treatment Guidelines and Expert Consensus<\/strong><\/h2>\n\n\n\nTreatment guidelines and expert consensus play a central role in vitiligo care because there is no single treatment that works for everyone. Vitiligo management often depends on multiple factors, including age, skin type, disease activity, affected body areas, medical history, and personal treatment preferences. Because of this variability, clinicians rely on structured guidance and expert recommendations to support more consistent and balanced decision-making. These frameworks help ensure patients receive care that is both evidence-informed and individualised.<\/p>\n\n\n\n
\n- Supporting Consistent Clinical Decisions: <\/strong>Expert groups such as the International Vitiligo Task Force help develop recommendations that guide diagnosis and treatment planning. These resources support clinicians when evidence is evolving or when clear-cut answers are not always available.<\/li>\n\n\n\n
- Helping Choose Between Treatment Options: <\/strong>Guidelines often help clinicians decide between topical treatments, phototherapy, combination therapies, and newer targeted approaches. This ensures treatment selection is based on clinical suitability rather than a one-size-fits-all method.<\/li>\n\n\n\n
- Recognising When Less Intensive Care Is Appropriate: <\/strong>Not all patients require aggressive treatment. In some cases, monitoring, camouflage techniques, psychological support, or a slower approach may be more appropriate depending on the individual situation and preferences.<\/li>\n\n\n\n
- Encouraging Shared Decision-Making: <\/strong>Good vitiligo care is built on collaboration between patient and dermatologist. Treatment decisions should reflect both medical guidance and patient goals, ensuring a personalised and realistic care plan.<\/li>\n<\/ul>\n\n\n\n
Expert consensus and clinical guidelines provide an important foundation for vitiligo management, especially in areas where evidence is still developing. They help clinicians make more consistent and informed treatment decisions while still allowing flexibility for individual needs. Conferences and guideline discussions reinforce the importance of tailoring care rather than applying rigid protocols. Ultimately, the best outcomes come from shared decision-making that balances medical expertise with patient preferences and expectations.<\/p>\n\n\n\n
Topical Treatments and Their Role<\/strong><\/h2>\n\n\n\nTopical treatments remain a key part of vitiligo management. These include options such as topical corticosteroids, calcineurin inhibitors, and newer targeted topical therapies where available. EADV sessions often discuss where each of these treatments fits best, which body areas respond more effectively, and how long therapy should be continued before assessing results.<\/p>\n\n\n\n
Vitiligo treatment usually requires patience, as repigmentation can take several months to become visible. In the early stages, changes may be subtle, and stopping treatment too soon can lead to disappointment or the impression that it is not working, even when progress may still be developing.<\/p>\n\n\n\n
At the same time, topical treatments need careful supervision. For example, topical steroids should not be used continuously without review, especially on sensitive areas such as the face, eyelids, or skin folds. Dermatology-led care ensures that treatment is used safely, appropriately, and for the right duration, with EADV discussions helping clinicians refine these practical decisions.<\/p>\n\n\n\n
Phototherapy in Vitiligo Care<\/strong><\/h2>\n\n\n\nPhototherapy is an important and well-established part of vitiligo treatment. Narrowband ultraviolet B (NB-UVB) phototherapy has been used for many years and can help stimulate repigmentation when used consistently under medical supervision.<\/p>\n\n\n\n
EADV 2025 included research discussions on the role of phototherapy in segmental vitiligo, particularly in the context of newer treatments such as Janus kinase inhibitors. This highlights that phototherapy is still relevant, even as newer therapeutic options continue to emerge.<\/p>\n\n\n\n
Rather than replacing older approaches, modern vitiligo care often focuses on how different treatments can be combined, sequenced, or selected based on the individual patient. Phototherapy may still be especially useful in certain cases, depending on disease extent, location, access to treatment facilities, and patient preference.<\/p>\n\n\n\n
However, phototherapy also requires commitment and consistency. It often involves regular clinic visits over several months, which may not be practical for everyone due to work, study, travel, or family responsibilities. EADV discussions increasingly emphasise this real-world aspect, ensuring treatment plans are not only clinically effective but also realistic and sustainable for the patient\u2019s daily life.<\/p>\n\n\n\n
JAK Inhibitors and Targeted Treatment Discussions<\/strong><\/h2>\n\n\n\nOne of the most active areas in vitiligo research is targeted therapy, especially treatments linked to the JAK-STAT signalling pathway. JAK inhibitors have gained attention because they act on specific immune pathways involved in inflammatory and autoimmune skin conditions.<\/p>\n\n\n\n
EADV scientific programmes have included focused sessions on JAK inhibitors, reflecting their growing importance across dermatology. EADV 2025 updates also noted that JAK and TYK2 inhibitors are expanding in clinical use, although larger controlled studies are still needed to fully confirm long-term effectiveness, safety, and optimal use in different patient groups.<\/p>\n\n\n\n
In vitiligo, these treatments are particularly relevant because current options can be helpful but often produce slow or variable results. Targeted therapies raise important clinical questions around patient selection, treatment duration, combination with phototherapy, and long-term safety, which are all carefully discussed in specialist conferences before being applied in routine care.<\/p>\n\n\n\n
Long-Term Safety and Durability of Results<\/strong><\/h2>\n\n\n\nVitiligo care is not only about restoring pigmentation, but also about maintaining those results safely over time. This is why EADV sessions often focus on durability of response, relapse rates, maintenance therapy, and long-term safety of treatments.<\/p>\n\n\n\n
Research discussed around EADV meetings has explored longer-term outcomes for treatments such as topical ruxolitinib in vitiligo. This is important because vitiligo is usually a chronic condition, and short-term improvement does not always reflect how stable results will be over time.<\/p>\n\n\n\n
Clinicians need to understand whether repigmentation is maintained, whether vitiligo returns after stopping treatment, and whether ongoing therapy is required. They also consider side effects over longer use and how outcomes may differ across body sites such as the face, hands, and feet.<\/p>\n\n\n\n
Segmental Vitiligo and Special Patterns<\/strong><\/h2>\n\n\n\nVitiligo is not a single uniform condition in clinical practice. Segmental vitiligo typically affects one side or a specific segment of the body and often behaves differently from non-segmental vitiligo. It may stabilise earlier, but it can also respond differently to certain treatments.<\/p>\n\n\n\n
Because of these differences, EADV sessions often discuss tailored treatment strategies for segmental vitiligo. This can include phototherapy in selected cases, surgical options for stable disease in specialist centres, and newer medical treatments where appropriate.<\/p>\n\n\n\n
The key message is that classification matters. A dermatologist needs to assess the exact type of vitiligo, whether it is active or stable, its location, and how it is progressing before recommending a treatment plan. This helps ensure that patients receive realistic, individualised advice rather than general information that may not apply to their specific condition.<\/p>\n\n\n\n
Vitiligo in Children and Young People<\/strong><\/h2>\n\n\n\nVitiligo in children is an important area of discussion in dermatology. When a child develops vitiligo, it is common for parents to feel anxious about progression, treatment safety, school experiences, and the possibility of emotional impact or teasing.<\/p>\n\n\n\n
EADV sessions encourage clinicians to take a balanced approach, recognising that children are not simply small adults. Treatment decisions need to consider age, skin sensitivity, emotional wellbeing, and how practical it is for families to follow a treatment plan consistently over time.<\/p>\n\n\n\n
The psychological impact is also important. Children may not always express distress directly, but changes such as avoiding photographs, withdrawing socially, or becoming more self-conscious can indicate how the condition is affecting them. EADV discussions highlight the importance of looking beyond skin changes and considering the child\u2019s overall wellbeing.<\/p>\n\n\n\n
Skin of Colour and Vitiligo<\/strong><\/h2>\n\n\n\n![\"\"](\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-54-1024x559.jpg\")
<\/figure>\n\n\n\nVitiligo can affect people of all skin types, but its visibility often varies depending on natural skin tone. On darker skin, depigmented patches may appear more noticeable because the contrast between affected and unaffected skin is greater. This can sometimes increase social attention and emotional impact.<\/p>\n\n\n\n
EADV discussions on skin of colour, pigmentation, and treatment response are important because they highlight that vitiligo is not experienced in the same way by everyone. A small patch on the face, for example, may have a significant effect on confidence, identity, or cultural perception, even if it is medically limited in size.<\/p>\n\n\n\n
Skin type can also influence treatment choices and response. Dermatologists may need to consider risks such as post-inflammatory pigment changes, irritation, or uneven repigmentation, and ensure that advice on sun protection is clear and appropriate for all skin tones. EADV\u2019s international setting helps bring these perspectives together so care can be more inclusive, personalised, and realistic.<\/p>\n\n\n\n
Psychological Impact and Quality of Life<\/strong><\/h2>\n\n\n\nOne of the most important aspects of modern vitiligo care is its impact on quality of life. While vitiligo is not physically painful in most cases, it can have a significant emotional and psychological effect. Many people experience feelings such as self-consciousness, frustration, embarrassment, or exhaustion from repeatedly explaining their condition to others. These emotional responses can be just as important to address as the physical changes in skin appearance.<\/p>\n\n\n\n
\n- Emotional and Social Impact: <\/strong>Vitiligo can affect confidence and social comfort. Some individuals may feel hesitant in situations such as social gatherings, swimming, photography, dating, or professional environments due to concerns about appearance or attention.<\/li>\n\n\n\n
- Variation Between Individuals: <\/strong>The psychological impact of vitiligo is highly individual. Two people with the same level of skin involvement may experience it very differently, with one feeling unaffected and another experiencing significant emotional distress.<\/li>\n\n\n\n
- Importance of Patient Experience in Care: <\/strong>Modern dermatology emphasises patient-reported outcomes rather than focusing only on visible skin involvement. Understanding how vitiligo affects daily life helps clinicians provide more meaningful and personalised care.<\/li>\n\n\n\n
- Influence on Treatment Planning and Support: <\/strong>A patient\u2019s emotional wellbeing can influence treatment decisions, follow-up schedules, and support options. In some cases, psychological support or counselling may be an important part of overall management.<\/li>\n<\/ul>\n\n\n\n
Vitiligo care is not only about treating skin changes but also about understanding the emotional and social impact of the condition. Conferences and EADV discussions continue to reinforce the importance of quality of life in clinical decision-making. This approach helps dermatologists look beyond patch size and focus on how the condition affects each individual person. Ultimately, effective care should combine medical treatment with empathy, support, and attention to psychological wellbeing.<\/p>\n\n\n\n
Measuring Treatment Success<\/strong><\/h2>\n\n\n\nVitiligo treatment success is not always easy to define. Unlike some conditions where improvement is obvious, vitiligo often changes gradually and unevenly across different areas of the body, which can make progress harder to judge.<\/p>\n\n\n\n
Repigmentation may begin as small pigment spots around hair follicles, and it may appear earlier on the face compared with areas such as the hands or feet. Some areas may respond well to treatment while others show minimal change, even within the same person.<\/p>\n\n\n\n
EADV sessions often focus on how to measure outcomes more consistently, using tools such as clinical scoring systems, serial photographs, patient feedback, disease stability assessment, and quality-of-life measures. This helps create a clearer and more structured understanding of whether a treatment is truly working.<\/p>\n\n\n\n
For patients, this is important because unclear expectations can be frustrating. If you are simply told to \u201ccontinue treatment and wait,\u201d it may not be obvious what improvement should look like or when a change in approach should be considered. Better measurement supports clearer communication and more informed decisions between patients and clinicians, while also improving the quality and comparability of research studies.<\/p>\n\n\n\n
Combination Treatment Approaches<\/strong><\/h2>\n\n\n\nVitiligo treatment is often not based on a single long-term option, but rather on a combination of therapies tailored to the individual. Dermatologists may adjust treatment strategies depending on disease activity, response over time, and the areas of skin involved. This flexible approach allows care to be adapted rather than fixed, which is particularly important in a condition that can behave unpredictably. EADV sessions frequently explore how these combinations can be used effectively in real clinical practice.<\/p>\n\n\n\n
\n- Using Topical and Light-Based Therapies Together: <\/strong>A common approach involves combining topical treatments with phototherapy. Light-based therapy may help stimulate pigment production, while topical treatments can help reduce inflammation and support repigmentation.<\/li>\n\n\n\n
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n
- Balancing Benefits and Practical Challenges: <\/strong>While combination therapy can be effective, it also needs careful planning. More treatments do not always mean better results and may increase cost, side effects, or daily treatment burden for the patient.<\/li>\n\n\n\n
- Personalised Treatment Selection: <\/strong>The most effective combination is not necessarily the most intensive one. It is the approach that best fits the patient\u2019s condition, lifestyle, safety considerations, and personal treatment goals.<\/li>\n<\/ul>\n\n\n\n
Combination treatment approaches in vitiligo care highlight the importance of flexibility and personalisation in dermatology. EADV discussions continue to show that thoughtful pairing of therapies can improve outcomes when used appropriately. However, careful planning is essential to avoid unnecessary complexity or treatment burden. Ultimately, the best care is tailored to the individual, balancing effectiveness, safety, and long-term manageability.<\/p>\n\n\n\n
How EADV Sessions Influence Clinical Practice<\/strong><\/h2>\n\n\n\nEADV congress sessions do not usually change clinical practice overnight, but they do play an important role in shaping how dermatologists think, discuss, and refine patient care. A clinician may attend a session on new research and later apply that learning when reviewing treatment plans, advising patients, or deciding when specialist referral is needed.<\/p>\n\n\n\n
These sessions influence practice in several ways. They highlight emerging treatments, clarify where evidence is strong, and identify areas where more research is still needed. They also encourage doctors to focus more on patient experience and quality of life, not just clinical trial results.<\/p>\n\n\n\n
Over time, this collective learning can influence guidelines, prescribing patterns, medical education, and how clinicians communicate with patients. For example, if research consistently highlights the importance of early treatment in active vitiligo, clinicians may become more attentive to early signs of progression and intervene sooner.<\/p>\n\n\n\n
This is how conference evidence gradually translates into real-world care. It moves from presentations and discussions at EADV into everyday consultations, helping improve both medical decision-making and patient understanding.<\/p>\n\n\n\n
What Patients Can Take from EADV Vitiligo Discussions<\/strong><\/h2>\n\n\n\n![\"\"](\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-7-4-1024x559.jpg\")
<\/figure>\n\n\n\nIf you are living with vitiligo, you do not need to follow every scientific detail presented at EADV. However, it can be helpful to understand the general direction that modern care is taking.<\/p>\n\n\n\n
Vitiligo treatment is becoming more personalised, with greater focus on immune mechanisms, disease activity, timing of intervention, quality of life, and long-term management rather than short-term cosmetic change alone.<\/p>\n\n\n\n
At the same time, newer targeted treatments are emerging, but this does not mean older approaches have become irrelevant. Topical treatments, phototherapy, psychological support, camouflage techniques, and lifestyle guidance still play an important role depending on the individual\u2019s needs and condition.<\/p>\n\n\n\n
It is also important to be cautious with online information, as vitiligo can be emotionally challenging and may attract exaggerated claims or unrealistic promises. EADV discussions are valuable because they are based on scientific evidence, clinical experience, and peer-reviewed research rather than anecdotal reports or marketing claims.<\/p>\n\n\n\n
Future Directions in Vitiligo Research<\/strong><\/h2>\n\n\n\nThe future of vitiligo research is likely to focus on more targeted, personalised, and measurable treatment approaches. Researchers are continuing to explore immune pathways, genetic influences, biomarkers, relapse prevention, maintenance strategies, and combination therapies. Recent reviews summarising advances between 2020 and 2025 show how active and rapidly evolving this field has become.<\/p>\n\n\n\n
However, not every new development will automatically become standard care. Some treatments may require more long-term safety data, while others may only be effective in specific patient groups. Practical factors such as access, cost, and availability will also influence how widely new therapies are used in real-world settings.<\/p>\n\n\n\n
Despite these challenges, the overall direction is encouraging. Vitiligo is receiving significantly more scientific attention than in the past, and there is a stronger focus on patient-reported outcomes, quality of life, and shared decision-making alongside clinical results.<\/p>\n\n\n\n
EADV sessions play an important role in bringing these elements together. They provide a platform where scientific research, clinical experience, and patient perspectives can be discussed and refined, helping shape the future direction of vitiligo care.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n1. What is the main focus of EADV vitiligo sessions?
<\/strong>EADV vitiligo sessions focus on advancing understanding of Vitiligo through research updates, clinical guidelines, treatment innovations, and real-world patient care strategies.<\/p>\n\n\n\n2. Why is vitiligo discussed at European Academy of Dermatology and Venereology meetings?
<\/strong>Because vitiligo is a complex immune-mediated condition, EADV brings together experts to share evidence, improve treatment approaches, and address both medical and psychological aspects of care.<\/p>\n\n\n\n3. What new treatments are discussed in EADV vitiligo sessions?
<\/strong>Sessions often cover topical therapies, phototherapy, and newer targeted treatments such as JAK pathway-based approaches, including discussion of JAK inhibitors.<\/p>\n\n\n\n4. Do EADV sessions focus only on medical treatments?
<\/strong>No. They also focus on psychological impact, quality of life, disease classification, patient experience, and long-term management strategies for vitiligo.<\/p>\n\n\n\n5. How is vitiligo classified in EADV discussions?
<\/strong>Dermatologists discuss whether vitiligo is segmental or non-segmental, stable or active, and how different patterns affect treatment response and outcomes.<\/p>\n\n\n\n6. What role does phototherapy play in vitiligo treatment?
<\/strong>Phototherapy, especially narrowband UVB, remains an important treatment option and is often combined with topical or newer therapies to improve repigmentation.<\/p>\n\n\n\n7. Are JAK inhibitors a cure for vitiligo?
<\/strong>No. JAK inhibitors are promising targeted therapies that may help repigmentation, but they are not a cure and require more long-term safety and effectiveness data.<\/p>\n\n\n\n8. How do EADV sessions address psychological impact?
<\/strong>They highlight that vitiligo can significantly affect confidence, social life, and emotional wellbeing, and encourage integrating psychological support into treatment planning.<\/p>\n\n\n\n9. Do all patients respond the same way to vitiligo treatments?
<\/strong>No. Treatment response varies depending on skin type, disease activity, location of patches, and individual immune response, which is why personalised care is emphasised.<\/p>\n\n\n\n10. What is the future direction of vitiligo research discussed at EADV?
<\/strong>Future research focuses on targeted therapies, immune pathways, relapse prevention, combination treatments, and improving long-term outcomes while prioritising patient quality of life.<\/p>\n\n\n\nFinal Thoughts: The Evolving Understanding of Vitiligo Care at EADV<\/strong><\/h2>\n\n\n\nEADV vitiligo sessions highlight how rapidly this field is evolving, moving beyond simple repigmentation approaches towards a more complete understanding of Vitiligo as an immune-mediated condition. These discussions bring together new research, emerging therapies such as targeted treatments, and long-standing approaches like topical therapy and phototherapy, while also placing strong emphasis on quality of life, psychological wellbeing, and personalised care.<\/p>\n\n\n\n
The overall direction is clear: vitiligo management is becoming more individualised, evidence-driven, and focused on long-term outcomes rather than short-term results alone. If you\u2019re looking for Vitiligo treatment in London<\/a>, you can reach out to us at the London Dermatology Centre to book a consultation with one of our specialists.<\/p>\n\n\n\nReferences:<\/strong><\/h2>\n\n\n\n1. Shuaib, L. et al., 2025. Efficacy of Janus kinase inhibitor combined with phototherapy in non\u2011segmental vitiligo: systematic review and meta\u2011analysis. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12777791\/<\/a><\/p>\n\n\n\n2. 308\u202fnm excimer laser combined with JAK inhibitors for adult localized non\u2011segmental vitiligo: a multicenter randomized controlled trial. https:\/\/pubmed.ncbi.nlm.nih.gov\/40682379\/<\/a><\/p>\n\n\n\n3. Zhou, B. et al., 2024. Combination therapy with baricitinib and narrowband ultraviolet B for active non\u2011segmental vitiligo: a retrospective controlled study. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11668684\/<\/a><\/p>\n\n\n\n4. Mumford, J. et al., 2023. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB\u2011UVB phototherapy. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10015970\/<\/a><\/p>\n\n\n\n5. Combination therapy with 308\u2011nm excimer laser, topical tacrolimus, and short\u2011term systemic corticosteroids for segmental vitiligo. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0190962215015108<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such […]<\/p>\n","protected":false},"author":4,"featured_media":6013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"Uncategorized<\/a>","rttpg_excerpt":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such…","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6049,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6013"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/figure>\n\n\n\nVitiligo sessions at EADV often focus on how dermatologists assess and classify the condition. This is important because vitiligo is not the same in every person. The pattern, speed of change, and response to treatment can vary widely.<\/p>\n\n\n\n
Some people have small, stable patches that remain unchanged for long periods, while others experience more active disease with spreading depigmentation. The areas affected can also differ, with the face, hands, feet, and other body sites showing different behaviours and treatment responses.<\/p>\n\n\n\n
Segmental vitiligo behaves differently from non-segmental vitiligo, and this distinction plays a key role in planning treatment. EADV discussions also highlight the importance of assessing disease extent, progression, previous treatments, and impact on quality of life to guide realistic expectations and more personalised care.<\/p>\n\n\n\n
Treatment Guidelines and Expert Consensus<\/strong><\/h2>\n\n\n\nTreatment guidelines and expert consensus play a central role in vitiligo care because there is no single treatment that works for everyone. Vitiligo management often depends on multiple factors, including age, skin type, disease activity, affected body areas, medical history, and personal treatment preferences. Because of this variability, clinicians rely on structured guidance and expert recommendations to support more consistent and balanced decision-making. These frameworks help ensure patients receive care that is both evidence-informed and individualised.<\/p>\n\n\n\n
\n- Supporting Consistent Clinical Decisions: <\/strong>Expert groups such as the International Vitiligo Task Force help develop recommendations that guide diagnosis and treatment planning. These resources support clinicians when evidence is evolving or when clear-cut answers are not always available.<\/li>\n\n\n\n
- Helping Choose Between Treatment Options: <\/strong>Guidelines often help clinicians decide between topical treatments, phototherapy, combination therapies, and newer targeted approaches. This ensures treatment selection is based on clinical suitability rather than a one-size-fits-all method.<\/li>\n\n\n\n
- Recognising When Less Intensive Care Is Appropriate: <\/strong>Not all patients require aggressive treatment. In some cases, monitoring, camouflage techniques, psychological support, or a slower approach may be more appropriate depending on the individual situation and preferences.<\/li>\n\n\n\n
- Encouraging Shared Decision-Making: <\/strong>Good vitiligo care is built on collaboration between patient and dermatologist. Treatment decisions should reflect both medical guidance and patient goals, ensuring a personalised and realistic care plan.<\/li>\n<\/ul>\n\n\n\n
Expert consensus and clinical guidelines provide an important foundation for vitiligo management, especially in areas where evidence is still developing. They help clinicians make more consistent and informed treatment decisions while still allowing flexibility for individual needs. Conferences and guideline discussions reinforce the importance of tailoring care rather than applying rigid protocols. Ultimately, the best outcomes come from shared decision-making that balances medical expertise with patient preferences and expectations.<\/p>\n\n\n\n
Topical Treatments and Their Role<\/strong><\/h2>\n\n\n\nTopical treatments remain a key part of vitiligo management. These include options such as topical corticosteroids, calcineurin inhibitors, and newer targeted topical therapies where available. EADV sessions often discuss where each of these treatments fits best, which body areas respond more effectively, and how long therapy should be continued before assessing results.<\/p>\n\n\n\n
Vitiligo treatment usually requires patience, as repigmentation can take several months to become visible. In the early stages, changes may be subtle, and stopping treatment too soon can lead to disappointment or the impression that it is not working, even when progress may still be developing.<\/p>\n\n\n\n
At the same time, topical treatments need careful supervision. For example, topical steroids should not be used continuously without review, especially on sensitive areas such as the face, eyelids, or skin folds. Dermatology-led care ensures that treatment is used safely, appropriately, and for the right duration, with EADV discussions helping clinicians refine these practical decisions.<\/p>\n\n\n\n
Phototherapy in Vitiligo Care<\/strong><\/h2>\n\n\n\nPhototherapy is an important and well-established part of vitiligo treatment. Narrowband ultraviolet B (NB-UVB) phototherapy has been used for many years and can help stimulate repigmentation when used consistently under medical supervision.<\/p>\n\n\n\n
EADV 2025 included research discussions on the role of phototherapy in segmental vitiligo, particularly in the context of newer treatments such as Janus kinase inhibitors. This highlights that phototherapy is still relevant, even as newer therapeutic options continue to emerge.<\/p>\n\n\n\n
Rather than replacing older approaches, modern vitiligo care often focuses on how different treatments can be combined, sequenced, or selected based on the individual patient. Phototherapy may still be especially useful in certain cases, depending on disease extent, location, access to treatment facilities, and patient preference.<\/p>\n\n\n\n
However, phototherapy also requires commitment and consistency. It often involves regular clinic visits over several months, which may not be practical for everyone due to work, study, travel, or family responsibilities. EADV discussions increasingly emphasise this real-world aspect, ensuring treatment plans are not only clinically effective but also realistic and sustainable for the patient\u2019s daily life.<\/p>\n\n\n\n
JAK Inhibitors and Targeted Treatment Discussions<\/strong><\/h2>\n\n\n\nOne of the most active areas in vitiligo research is targeted therapy, especially treatments linked to the JAK-STAT signalling pathway. JAK inhibitors have gained attention because they act on specific immune pathways involved in inflammatory and autoimmune skin conditions.<\/p>\n\n\n\n
EADV scientific programmes have included focused sessions on JAK inhibitors, reflecting their growing importance across dermatology. EADV 2025 updates also noted that JAK and TYK2 inhibitors are expanding in clinical use, although larger controlled studies are still needed to fully confirm long-term effectiveness, safety, and optimal use in different patient groups.<\/p>\n\n\n\n
In vitiligo, these treatments are particularly relevant because current options can be helpful but often produce slow or variable results. Targeted therapies raise important clinical questions around patient selection, treatment duration, combination with phototherapy, and long-term safety, which are all carefully discussed in specialist conferences before being applied in routine care.<\/p>\n\n\n\n
Long-Term Safety and Durability of Results<\/strong><\/h2>\n\n\n\nVitiligo care is not only about restoring pigmentation, but also about maintaining those results safely over time. This is why EADV sessions often focus on durability of response, relapse rates, maintenance therapy, and long-term safety of treatments.<\/p>\n\n\n\n
Research discussed around EADV meetings has explored longer-term outcomes for treatments such as topical ruxolitinib in vitiligo. This is important because vitiligo is usually a chronic condition, and short-term improvement does not always reflect how stable results will be over time.<\/p>\n\n\n\n
Clinicians need to understand whether repigmentation is maintained, whether vitiligo returns after stopping treatment, and whether ongoing therapy is required. They also consider side effects over longer use and how outcomes may differ across body sites such as the face, hands, and feet.<\/p>\n\n\n\n
Segmental Vitiligo and Special Patterns<\/strong><\/h2>\n\n\n\nVitiligo is not a single uniform condition in clinical practice. Segmental vitiligo typically affects one side or a specific segment of the body and often behaves differently from non-segmental vitiligo. It may stabilise earlier, but it can also respond differently to certain treatments.<\/p>\n\n\n\n
Because of these differences, EADV sessions often discuss tailored treatment strategies for segmental vitiligo. This can include phototherapy in selected cases, surgical options for stable disease in specialist centres, and newer medical treatments where appropriate.<\/p>\n\n\n\n
The key message is that classification matters. A dermatologist needs to assess the exact type of vitiligo, whether it is active or stable, its location, and how it is progressing before recommending a treatment plan. This helps ensure that patients receive realistic, individualised advice rather than general information that may not apply to their specific condition.<\/p>\n\n\n\n
Vitiligo in Children and Young People<\/strong><\/h2>\n\n\n\nVitiligo in children is an important area of discussion in dermatology. When a child develops vitiligo, it is common for parents to feel anxious about progression, treatment safety, school experiences, and the possibility of emotional impact or teasing.<\/p>\n\n\n\n
EADV sessions encourage clinicians to take a balanced approach, recognising that children are not simply small adults. Treatment decisions need to consider age, skin sensitivity, emotional wellbeing, and how practical it is for families to follow a treatment plan consistently over time.<\/p>\n\n\n\n
The psychological impact is also important. Children may not always express distress directly, but changes such as avoiding photographs, withdrawing socially, or becoming more self-conscious can indicate how the condition is affecting them. EADV discussions highlight the importance of looking beyond skin changes and considering the child\u2019s overall wellbeing.<\/p>\n\n\n\n
Skin of Colour and Vitiligo<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nVitiligo can affect people of all skin types, but its visibility often varies depending on natural skin tone. On darker skin, depigmented patches may appear more noticeable because the contrast between affected and unaffected skin is greater. This can sometimes increase social attention and emotional impact.<\/p>\n\n\n\n
EADV discussions on skin of colour, pigmentation, and treatment response are important because they highlight that vitiligo is not experienced in the same way by everyone. A small patch on the face, for example, may have a significant effect on confidence, identity, or cultural perception, even if it is medically limited in size.<\/p>\n\n\n\n
Skin type can also influence treatment choices and response. Dermatologists may need to consider risks such as post-inflammatory pigment changes, irritation, or uneven repigmentation, and ensure that advice on sun protection is clear and appropriate for all skin tones. EADV\u2019s international setting helps bring these perspectives together so care can be more inclusive, personalised, and realistic.<\/p>\n\n\n\n
Psychological Impact and Quality of Life<\/strong><\/h2>\n\n\n\nOne of the most important aspects of modern vitiligo care is its impact on quality of life. While vitiligo is not physically painful in most cases, it can have a significant emotional and psychological effect. Many people experience feelings such as self-consciousness, frustration, embarrassment, or exhaustion from repeatedly explaining their condition to others. These emotional responses can be just as important to address as the physical changes in skin appearance.<\/p>\n\n\n\n
\n- Emotional and Social Impact: <\/strong>Vitiligo can affect confidence and social comfort. Some individuals may feel hesitant in situations such as social gatherings, swimming, photography, dating, or professional environments due to concerns about appearance or attention.<\/li>\n\n\n\n
- Variation Between Individuals: <\/strong>The psychological impact of vitiligo is highly individual. Two people with the same level of skin involvement may experience it very differently, with one feeling unaffected and another experiencing significant emotional distress.<\/li>\n\n\n\n
- Importance of Patient Experience in Care: <\/strong>Modern dermatology emphasises patient-reported outcomes rather than focusing only on visible skin involvement. Understanding how vitiligo affects daily life helps clinicians provide more meaningful and personalised care.<\/li>\n\n\n\n
- Influence on Treatment Planning and Support: <\/strong>A patient\u2019s emotional wellbeing can influence treatment decisions, follow-up schedules, and support options. In some cases, psychological support or counselling may be an important part of overall management.<\/li>\n<\/ul>\n\n\n\n
Vitiligo care is not only about treating skin changes but also about understanding the emotional and social impact of the condition. Conferences and EADV discussions continue to reinforce the importance of quality of life in clinical decision-making. This approach helps dermatologists look beyond patch size and focus on how the condition affects each individual person. Ultimately, effective care should combine medical treatment with empathy, support, and attention to psychological wellbeing.<\/p>\n\n\n\n
Measuring Treatment Success<\/strong><\/h2>\n\n\n\nVitiligo treatment success is not always easy to define. Unlike some conditions where improvement is obvious, vitiligo often changes gradually and unevenly across different areas of the body, which can make progress harder to judge.<\/p>\n\n\n\n
Repigmentation may begin as small pigment spots around hair follicles, and it may appear earlier on the face compared with areas such as the hands or feet. Some areas may respond well to treatment while others show minimal change, even within the same person.<\/p>\n\n\n\n
EADV sessions often focus on how to measure outcomes more consistently, using tools such as clinical scoring systems, serial photographs, patient feedback, disease stability assessment, and quality-of-life measures. This helps create a clearer and more structured understanding of whether a treatment is truly working.<\/p>\n\n\n\n
For patients, this is important because unclear expectations can be frustrating. If you are simply told to \u201ccontinue treatment and wait,\u201d it may not be obvious what improvement should look like or when a change in approach should be considered. Better measurement supports clearer communication and more informed decisions between patients and clinicians, while also improving the quality and comparability of research studies.<\/p>\n\n\n\n
Combination Treatment Approaches<\/strong><\/h2>\n\n\n\nVitiligo treatment is often not based on a single long-term option, but rather on a combination of therapies tailored to the individual. Dermatologists may adjust treatment strategies depending on disease activity, response over time, and the areas of skin involved. This flexible approach allows care to be adapted rather than fixed, which is particularly important in a condition that can behave unpredictably. EADV sessions frequently explore how these combinations can be used effectively in real clinical practice.<\/p>\n\n\n\n
\n- Using Topical and Light-Based Therapies Together: <\/strong>A common approach involves combining topical treatments with phototherapy. Light-based therapy may help stimulate pigment production, while topical treatments can help reduce inflammation and support repigmentation.<\/li>\n\n\n\n
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n
- Balancing Benefits and Practical Challenges: <\/strong>While combination therapy can be effective, it also needs careful planning. More treatments do not always mean better results and may increase cost, side effects, or daily treatment burden for the patient.<\/li>\n\n\n\n
- Personalised Treatment Selection: <\/strong>The most effective combination is not necessarily the most intensive one. It is the approach that best fits the patient\u2019s condition, lifestyle, safety considerations, and personal treatment goals.<\/li>\n<\/ul>\n\n\n\n
Combination treatment approaches in vitiligo care highlight the importance of flexibility and personalisation in dermatology. EADV discussions continue to show that thoughtful pairing of therapies can improve outcomes when used appropriately. However, careful planning is essential to avoid unnecessary complexity or treatment burden. Ultimately, the best care is tailored to the individual, balancing effectiveness, safety, and long-term manageability.<\/p>\n\n\n\n
How EADV Sessions Influence Clinical Practice<\/strong><\/h2>\n\n\n\nEADV congress sessions do not usually change clinical practice overnight, but they do play an important role in shaping how dermatologists think, discuss, and refine patient care. A clinician may attend a session on new research and later apply that learning when reviewing treatment plans, advising patients, or deciding when specialist referral is needed.<\/p>\n\n\n\n
These sessions influence practice in several ways. They highlight emerging treatments, clarify where evidence is strong, and identify areas where more research is still needed. They also encourage doctors to focus more on patient experience and quality of life, not just clinical trial results.<\/p>\n\n\n\n
Over time, this collective learning can influence guidelines, prescribing patterns, medical education, and how clinicians communicate with patients. For example, if research consistently highlights the importance of early treatment in active vitiligo, clinicians may become more attentive to early signs of progression and intervene sooner.<\/p>\n\n\n\n
This is how conference evidence gradually translates into real-world care. It moves from presentations and discussions at EADV into everyday consultations, helping improve both medical decision-making and patient understanding.<\/p>\n\n\n\n
What Patients Can Take from EADV Vitiligo Discussions<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nIf you are living with vitiligo, you do not need to follow every scientific detail presented at EADV. However, it can be helpful to understand the general direction that modern care is taking.<\/p>\n\n\n\n
Vitiligo treatment is becoming more personalised, with greater focus on immune mechanisms, disease activity, timing of intervention, quality of life, and long-term management rather than short-term cosmetic change alone.<\/p>\n\n\n\n
At the same time, newer targeted treatments are emerging, but this does not mean older approaches have become irrelevant. Topical treatments, phototherapy, psychological support, camouflage techniques, and lifestyle guidance still play an important role depending on the individual\u2019s needs and condition.<\/p>\n\n\n\n
It is also important to be cautious with online information, as vitiligo can be emotionally challenging and may attract exaggerated claims or unrealistic promises. EADV discussions are valuable because they are based on scientific evidence, clinical experience, and peer-reviewed research rather than anecdotal reports or marketing claims.<\/p>\n\n\n\n
Future Directions in Vitiligo Research<\/strong><\/h2>\n\n\n\nThe future of vitiligo research is likely to focus on more targeted, personalised, and measurable treatment approaches. Researchers are continuing to explore immune pathways, genetic influences, biomarkers, relapse prevention, maintenance strategies, and combination therapies. Recent reviews summarising advances between 2020 and 2025 show how active and rapidly evolving this field has become.<\/p>\n\n\n\n
However, not every new development will automatically become standard care. Some treatments may require more long-term safety data, while others may only be effective in specific patient groups. Practical factors such as access, cost, and availability will also influence how widely new therapies are used in real-world settings.<\/p>\n\n\n\n
Despite these challenges, the overall direction is encouraging. Vitiligo is receiving significantly more scientific attention than in the past, and there is a stronger focus on patient-reported outcomes, quality of life, and shared decision-making alongside clinical results.<\/p>\n\n\n\n
EADV sessions play an important role in bringing these elements together. They provide a platform where scientific research, clinical experience, and patient perspectives can be discussed and refined, helping shape the future direction of vitiligo care.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n1. What is the main focus of EADV vitiligo sessions?
<\/strong>EADV vitiligo sessions focus on advancing understanding of Vitiligo through research updates, clinical guidelines, treatment innovations, and real-world patient care strategies.<\/p>\n\n\n\n2. Why is vitiligo discussed at European Academy of Dermatology and Venereology meetings?
<\/strong>Because vitiligo is a complex immune-mediated condition, EADV brings together experts to share evidence, improve treatment approaches, and address both medical and psychological aspects of care.<\/p>\n\n\n\n3. What new treatments are discussed in EADV vitiligo sessions?
<\/strong>Sessions often cover topical therapies, phototherapy, and newer targeted treatments such as JAK pathway-based approaches, including discussion of JAK inhibitors.<\/p>\n\n\n\n4. Do EADV sessions focus only on medical treatments?
<\/strong>No. They also focus on psychological impact, quality of life, disease classification, patient experience, and long-term management strategies for vitiligo.<\/p>\n\n\n\n5. How is vitiligo classified in EADV discussions?
<\/strong>Dermatologists discuss whether vitiligo is segmental or non-segmental, stable or active, and how different patterns affect treatment response and outcomes.<\/p>\n\n\n\n6. What role does phototherapy play in vitiligo treatment?
<\/strong>Phototherapy, especially narrowband UVB, remains an important treatment option and is often combined with topical or newer therapies to improve repigmentation.<\/p>\n\n\n\n7. Are JAK inhibitors a cure for vitiligo?
<\/strong>No. JAK inhibitors are promising targeted therapies that may help repigmentation, but they are not a cure and require more long-term safety and effectiveness data.<\/p>\n\n\n\n8. How do EADV sessions address psychological impact?
<\/strong>They highlight that vitiligo can significantly affect confidence, social life, and emotional wellbeing, and encourage integrating psychological support into treatment planning.<\/p>\n\n\n\n9. Do all patients respond the same way to vitiligo treatments?
<\/strong>No. Treatment response varies depending on skin type, disease activity, location of patches, and individual immune response, which is why personalised care is emphasised.<\/p>\n\n\n\n10. What is the future direction of vitiligo research discussed at EADV?
<\/strong>Future research focuses on targeted therapies, immune pathways, relapse prevention, combination treatments, and improving long-term outcomes while prioritising patient quality of life.<\/p>\n\n\n\nFinal Thoughts: The Evolving Understanding of Vitiligo Care at EADV<\/strong><\/h2>\n\n\n\nEADV vitiligo sessions highlight how rapidly this field is evolving, moving beyond simple repigmentation approaches towards a more complete understanding of Vitiligo as an immune-mediated condition. These discussions bring together new research, emerging therapies such as targeted treatments, and long-standing approaches like topical therapy and phototherapy, while also placing strong emphasis on quality of life, psychological wellbeing, and personalised care.<\/p>\n\n\n\n
The overall direction is clear: vitiligo management is becoming more individualised, evidence-driven, and focused on long-term outcomes rather than short-term results alone. If you\u2019re looking for Vitiligo treatment in London<\/a>, you can reach out to us at the London Dermatology Centre to book a consultation with one of our specialists.<\/p>\n\n\n\nReferences:<\/strong><\/h2>\n\n\n\n1. Shuaib, L. et al., 2025. Efficacy of Janus kinase inhibitor combined with phototherapy in non\u2011segmental vitiligo: systematic review and meta\u2011analysis. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12777791\/<\/a><\/p>\n\n\n\n2. 308\u202fnm excimer laser combined with JAK inhibitors for adult localized non\u2011segmental vitiligo: a multicenter randomized controlled trial. https:\/\/pubmed.ncbi.nlm.nih.gov\/40682379\/<\/a><\/p>\n\n\n\n3. Zhou, B. et al., 2024. Combination therapy with baricitinib and narrowband ultraviolet B for active non\u2011segmental vitiligo: a retrospective controlled study. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11668684\/<\/a><\/p>\n\n\n\n4. Mumford, J. et al., 2023. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB\u2011UVB phototherapy. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10015970\/<\/a><\/p>\n\n\n\n5. Combination therapy with 308\u2011nm excimer laser, topical tacrolimus, and short\u2011term systemic corticosteroids for segmental vitiligo. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0190962215015108<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such […]<\/p>\n","protected":false},"author":4,"featured_media":6013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"Uncategorized<\/a>","rttpg_excerpt":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such…","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6049,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6013"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Expert consensus and clinical guidelines provide an important foundation for vitiligo management, especially in areas where evidence is still developing. They help clinicians make more consistent and informed treatment decisions while still allowing flexibility for individual needs. Conferences and guideline discussions reinforce the importance of tailoring care rather than applying rigid protocols. Ultimately, the best outcomes come from shared decision-making that balances medical expertise with patient preferences and expectations.<\/p>\n\n\n\n
Topical Treatments and Their Role<\/strong><\/h2>\n\n\n\nTopical treatments remain a key part of vitiligo management. These include options such as topical corticosteroids, calcineurin inhibitors, and newer targeted topical therapies where available. EADV sessions often discuss where each of these treatments fits best, which body areas respond more effectively, and how long therapy should be continued before assessing results.<\/p>\n\n\n\n
Vitiligo treatment usually requires patience, as repigmentation can take several months to become visible. In the early stages, changes may be subtle, and stopping treatment too soon can lead to disappointment or the impression that it is not working, even when progress may still be developing.<\/p>\n\n\n\n
At the same time, topical treatments need careful supervision. For example, topical steroids should not be used continuously without review, especially on sensitive areas such as the face, eyelids, or skin folds. Dermatology-led care ensures that treatment is used safely, appropriately, and for the right duration, with EADV discussions helping clinicians refine these practical decisions.<\/p>\n\n\n\n
Phototherapy in Vitiligo Care<\/strong><\/h2>\n\n\n\nPhototherapy is an important and well-established part of vitiligo treatment. Narrowband ultraviolet B (NB-UVB) phototherapy has been used for many years and can help stimulate repigmentation when used consistently under medical supervision.<\/p>\n\n\n\n
EADV 2025 included research discussions on the role of phototherapy in segmental vitiligo, particularly in the context of newer treatments such as Janus kinase inhibitors. This highlights that phototherapy is still relevant, even as newer therapeutic options continue to emerge.<\/p>\n\n\n\n
Rather than replacing older approaches, modern vitiligo care often focuses on how different treatments can be combined, sequenced, or selected based on the individual patient. Phototherapy may still be especially useful in certain cases, depending on disease extent, location, access to treatment facilities, and patient preference.<\/p>\n\n\n\n
However, phototherapy also requires commitment and consistency. It often involves regular clinic visits over several months, which may not be practical for everyone due to work, study, travel, or family responsibilities. EADV discussions increasingly emphasise this real-world aspect, ensuring treatment plans are not only clinically effective but also realistic and sustainable for the patient\u2019s daily life.<\/p>\n\n\n\n
JAK Inhibitors and Targeted Treatment Discussions<\/strong><\/h2>\n\n\n\nOne of the most active areas in vitiligo research is targeted therapy, especially treatments linked to the JAK-STAT signalling pathway. JAK inhibitors have gained attention because they act on specific immune pathways involved in inflammatory and autoimmune skin conditions.<\/p>\n\n\n\n
EADV scientific programmes have included focused sessions on JAK inhibitors, reflecting their growing importance across dermatology. EADV 2025 updates also noted that JAK and TYK2 inhibitors are expanding in clinical use, although larger controlled studies are still needed to fully confirm long-term effectiveness, safety, and optimal use in different patient groups.<\/p>\n\n\n\n
In vitiligo, these treatments are particularly relevant because current options can be helpful but often produce slow or variable results. Targeted therapies raise important clinical questions around patient selection, treatment duration, combination with phototherapy, and long-term safety, which are all carefully discussed in specialist conferences before being applied in routine care.<\/p>\n\n\n\n
Long-Term Safety and Durability of Results<\/strong><\/h2>\n\n\n\nVitiligo care is not only about restoring pigmentation, but also about maintaining those results safely over time. This is why EADV sessions often focus on durability of response, relapse rates, maintenance therapy, and long-term safety of treatments.<\/p>\n\n\n\n
Research discussed around EADV meetings has explored longer-term outcomes for treatments such as topical ruxolitinib in vitiligo. This is important because vitiligo is usually a chronic condition, and short-term improvement does not always reflect how stable results will be over time.<\/p>\n\n\n\n
Clinicians need to understand whether repigmentation is maintained, whether vitiligo returns after stopping treatment, and whether ongoing therapy is required. They also consider side effects over longer use and how outcomes may differ across body sites such as the face, hands, and feet.<\/p>\n\n\n\n
Segmental Vitiligo and Special Patterns<\/strong><\/h2>\n\n\n\nVitiligo is not a single uniform condition in clinical practice. Segmental vitiligo typically affects one side or a specific segment of the body and often behaves differently from non-segmental vitiligo. It may stabilise earlier, but it can also respond differently to certain treatments.<\/p>\n\n\n\n
Because of these differences, EADV sessions often discuss tailored treatment strategies for segmental vitiligo. This can include phototherapy in selected cases, surgical options for stable disease in specialist centres, and newer medical treatments where appropriate.<\/p>\n\n\n\n
The key message is that classification matters. A dermatologist needs to assess the exact type of vitiligo, whether it is active or stable, its location, and how it is progressing before recommending a treatment plan. This helps ensure that patients receive realistic, individualised advice rather than general information that may not apply to their specific condition.<\/p>\n\n\n\n
Vitiligo in Children and Young People<\/strong><\/h2>\n\n\n\nVitiligo in children is an important area of discussion in dermatology. When a child develops vitiligo, it is common for parents to feel anxious about progression, treatment safety, school experiences, and the possibility of emotional impact or teasing.<\/p>\n\n\n\n
EADV sessions encourage clinicians to take a balanced approach, recognising that children are not simply small adults. Treatment decisions need to consider age, skin sensitivity, emotional wellbeing, and how practical it is for families to follow a treatment plan consistently over time.<\/p>\n\n\n\n
The psychological impact is also important. Children may not always express distress directly, but changes such as avoiding photographs, withdrawing socially, or becoming more self-conscious can indicate how the condition is affecting them. EADV discussions highlight the importance of looking beyond skin changes and considering the child\u2019s overall wellbeing.<\/p>\n\n\n\n
Skin of Colour and Vitiligo<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nVitiligo can affect people of all skin types, but its visibility often varies depending on natural skin tone. On darker skin, depigmented patches may appear more noticeable because the contrast between affected and unaffected skin is greater. This can sometimes increase social attention and emotional impact.<\/p>\n\n\n\n
EADV discussions on skin of colour, pigmentation, and treatment response are important because they highlight that vitiligo is not experienced in the same way by everyone. A small patch on the face, for example, may have a significant effect on confidence, identity, or cultural perception, even if it is medically limited in size.<\/p>\n\n\n\n
Skin type can also influence treatment choices and response. Dermatologists may need to consider risks such as post-inflammatory pigment changes, irritation, or uneven repigmentation, and ensure that advice on sun protection is clear and appropriate for all skin tones. EADV\u2019s international setting helps bring these perspectives together so care can be more inclusive, personalised, and realistic.<\/p>\n\n\n\n
Psychological Impact and Quality of Life<\/strong><\/h2>\n\n\n\nOne of the most important aspects of modern vitiligo care is its impact on quality of life. While vitiligo is not physically painful in most cases, it can have a significant emotional and psychological effect. Many people experience feelings such as self-consciousness, frustration, embarrassment, or exhaustion from repeatedly explaining their condition to others. These emotional responses can be just as important to address as the physical changes in skin appearance.<\/p>\n\n\n\n
\n- Emotional and Social Impact: <\/strong>Vitiligo can affect confidence and social comfort. Some individuals may feel hesitant in situations such as social gatherings, swimming, photography, dating, or professional environments due to concerns about appearance or attention.<\/li>\n\n\n\n
- Variation Between Individuals: <\/strong>The psychological impact of vitiligo is highly individual. Two people with the same level of skin involvement may experience it very differently, with one feeling unaffected and another experiencing significant emotional distress.<\/li>\n\n\n\n
- Importance of Patient Experience in Care: <\/strong>Modern dermatology emphasises patient-reported outcomes rather than focusing only on visible skin involvement. Understanding how vitiligo affects daily life helps clinicians provide more meaningful and personalised care.<\/li>\n\n\n\n
- Influence on Treatment Planning and Support: <\/strong>A patient\u2019s emotional wellbeing can influence treatment decisions, follow-up schedules, and support options. In some cases, psychological support or counselling may be an important part of overall management.<\/li>\n<\/ul>\n\n\n\n
Vitiligo care is not only about treating skin changes but also about understanding the emotional and social impact of the condition. Conferences and EADV discussions continue to reinforce the importance of quality of life in clinical decision-making. This approach helps dermatologists look beyond patch size and focus on how the condition affects each individual person. Ultimately, effective care should combine medical treatment with empathy, support, and attention to psychological wellbeing.<\/p>\n\n\n\n
Measuring Treatment Success<\/strong><\/h2>\n\n\n\nVitiligo treatment success is not always easy to define. Unlike some conditions where improvement is obvious, vitiligo often changes gradually and unevenly across different areas of the body, which can make progress harder to judge.<\/p>\n\n\n\n
Repigmentation may begin as small pigment spots around hair follicles, and it may appear earlier on the face compared with areas such as the hands or feet. Some areas may respond well to treatment while others show minimal change, even within the same person.<\/p>\n\n\n\n
EADV sessions often focus on how to measure outcomes more consistently, using tools such as clinical scoring systems, serial photographs, patient feedback, disease stability assessment, and quality-of-life measures. This helps create a clearer and more structured understanding of whether a treatment is truly working.<\/p>\n\n\n\n
For patients, this is important because unclear expectations can be frustrating. If you are simply told to \u201ccontinue treatment and wait,\u201d it may not be obvious what improvement should look like or when a change in approach should be considered. Better measurement supports clearer communication and more informed decisions between patients and clinicians, while also improving the quality and comparability of research studies.<\/p>\n\n\n\n
Combination Treatment Approaches<\/strong><\/h2>\n\n\n\nVitiligo treatment is often not based on a single long-term option, but rather on a combination of therapies tailored to the individual. Dermatologists may adjust treatment strategies depending on disease activity, response over time, and the areas of skin involved. This flexible approach allows care to be adapted rather than fixed, which is particularly important in a condition that can behave unpredictably. EADV sessions frequently explore how these combinations can be used effectively in real clinical practice.<\/p>\n\n\n\n
\n- Using Topical and Light-Based Therapies Together: <\/strong>A common approach involves combining topical treatments with phototherapy. Light-based therapy may help stimulate pigment production, while topical treatments can help reduce inflammation and support repigmentation.<\/li>\n\n\n\n
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n
- Balancing Benefits and Practical Challenges: <\/strong>While combination therapy can be effective, it also needs careful planning. More treatments do not always mean better results and may increase cost, side effects, or daily treatment burden for the patient.<\/li>\n\n\n\n
- Personalised Treatment Selection: <\/strong>The most effective combination is not necessarily the most intensive one. It is the approach that best fits the patient\u2019s condition, lifestyle, safety considerations, and personal treatment goals.<\/li>\n<\/ul>\n\n\n\n
Combination treatment approaches in vitiligo care highlight the importance of flexibility and personalisation in dermatology. EADV discussions continue to show that thoughtful pairing of therapies can improve outcomes when used appropriately. However, careful planning is essential to avoid unnecessary complexity or treatment burden. Ultimately, the best care is tailored to the individual, balancing effectiveness, safety, and long-term manageability.<\/p>\n\n\n\n
How EADV Sessions Influence Clinical Practice<\/strong><\/h2>\n\n\n\nEADV congress sessions do not usually change clinical practice overnight, but they do play an important role in shaping how dermatologists think, discuss, and refine patient care. A clinician may attend a session on new research and later apply that learning when reviewing treatment plans, advising patients, or deciding when specialist referral is needed.<\/p>\n\n\n\n
These sessions influence practice in several ways. They highlight emerging treatments, clarify where evidence is strong, and identify areas where more research is still needed. They also encourage doctors to focus more on patient experience and quality of life, not just clinical trial results.<\/p>\n\n\n\n
Over time, this collective learning can influence guidelines, prescribing patterns, medical education, and how clinicians communicate with patients. For example, if research consistently highlights the importance of early treatment in active vitiligo, clinicians may become more attentive to early signs of progression and intervene sooner.<\/p>\n\n\n\n
This is how conference evidence gradually translates into real-world care. It moves from presentations and discussions at EADV into everyday consultations, helping improve both medical decision-making and patient understanding.<\/p>\n\n\n\n
What Patients Can Take from EADV Vitiligo Discussions<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nIf you are living with vitiligo, you do not need to follow every scientific detail presented at EADV. However, it can be helpful to understand the general direction that modern care is taking.<\/p>\n\n\n\n
Vitiligo treatment is becoming more personalised, with greater focus on immune mechanisms, disease activity, timing of intervention, quality of life, and long-term management rather than short-term cosmetic change alone.<\/p>\n\n\n\n
At the same time, newer targeted treatments are emerging, but this does not mean older approaches have become irrelevant. Topical treatments, phototherapy, psychological support, camouflage techniques, and lifestyle guidance still play an important role depending on the individual\u2019s needs and condition.<\/p>\n\n\n\n
It is also important to be cautious with online information, as vitiligo can be emotionally challenging and may attract exaggerated claims or unrealistic promises. EADV discussions are valuable because they are based on scientific evidence, clinical experience, and peer-reviewed research rather than anecdotal reports or marketing claims.<\/p>\n\n\n\n
Future Directions in Vitiligo Research<\/strong><\/h2>\n\n\n\nThe future of vitiligo research is likely to focus on more targeted, personalised, and measurable treatment approaches. Researchers are continuing to explore immune pathways, genetic influences, biomarkers, relapse prevention, maintenance strategies, and combination therapies. Recent reviews summarising advances between 2020 and 2025 show how active and rapidly evolving this field has become.<\/p>\n\n\n\n
However, not every new development will automatically become standard care. Some treatments may require more long-term safety data, while others may only be effective in specific patient groups. Practical factors such as access, cost, and availability will also influence how widely new therapies are used in real-world settings.<\/p>\n\n\n\n
Despite these challenges, the overall direction is encouraging. Vitiligo is receiving significantly more scientific attention than in the past, and there is a stronger focus on patient-reported outcomes, quality of life, and shared decision-making alongside clinical results.<\/p>\n\n\n\n
EADV sessions play an important role in bringing these elements together. They provide a platform where scientific research, clinical experience, and patient perspectives can be discussed and refined, helping shape the future direction of vitiligo care.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n1. What is the main focus of EADV vitiligo sessions?
<\/strong>EADV vitiligo sessions focus on advancing understanding of Vitiligo through research updates, clinical guidelines, treatment innovations, and real-world patient care strategies.<\/p>\n\n\n\n2. Why is vitiligo discussed at European Academy of Dermatology and Venereology meetings?
<\/strong>Because vitiligo is a complex immune-mediated condition, EADV brings together experts to share evidence, improve treatment approaches, and address both medical and psychological aspects of care.<\/p>\n\n\n\n3. What new treatments are discussed in EADV vitiligo sessions?
<\/strong>Sessions often cover topical therapies, phototherapy, and newer targeted treatments such as JAK pathway-based approaches, including discussion of JAK inhibitors.<\/p>\n\n\n\n4. Do EADV sessions focus only on medical treatments?
<\/strong>No. They also focus on psychological impact, quality of life, disease classification, patient experience, and long-term management strategies for vitiligo.<\/p>\n\n\n\n5. How is vitiligo classified in EADV discussions?
<\/strong>Dermatologists discuss whether vitiligo is segmental or non-segmental, stable or active, and how different patterns affect treatment response and outcomes.<\/p>\n\n\n\n6. What role does phototherapy play in vitiligo treatment?
<\/strong>Phototherapy, especially narrowband UVB, remains an important treatment option and is often combined with topical or newer therapies to improve repigmentation.<\/p>\n\n\n\n7. Are JAK inhibitors a cure for vitiligo?
<\/strong>No. JAK inhibitors are promising targeted therapies that may help repigmentation, but they are not a cure and require more long-term safety and effectiveness data.<\/p>\n\n\n\n8. How do EADV sessions address psychological impact?
<\/strong>They highlight that vitiligo can significantly affect confidence, social life, and emotional wellbeing, and encourage integrating psychological support into treatment planning.<\/p>\n\n\n\n9. Do all patients respond the same way to vitiligo treatments?
<\/strong>No. Treatment response varies depending on skin type, disease activity, location of patches, and individual immune response, which is why personalised care is emphasised.<\/p>\n\n\n\n10. What is the future direction of vitiligo research discussed at EADV?
<\/strong>Future research focuses on targeted therapies, immune pathways, relapse prevention, combination treatments, and improving long-term outcomes while prioritising patient quality of life.<\/p>\n\n\n\nFinal Thoughts: The Evolving Understanding of Vitiligo Care at EADV<\/strong><\/h2>\n\n\n\nEADV vitiligo sessions highlight how rapidly this field is evolving, moving beyond simple repigmentation approaches towards a more complete understanding of Vitiligo as an immune-mediated condition. These discussions bring together new research, emerging therapies such as targeted treatments, and long-standing approaches like topical therapy and phototherapy, while also placing strong emphasis on quality of life, psychological wellbeing, and personalised care.<\/p>\n\n\n\n
The overall direction is clear: vitiligo management is becoming more individualised, evidence-driven, and focused on long-term outcomes rather than short-term results alone. If you\u2019re looking for Vitiligo treatment in London<\/a>, you can reach out to us at the London Dermatology Centre to book a consultation with one of our specialists.<\/p>\n\n\n\nReferences:<\/strong><\/h2>\n\n\n\n1. Shuaib, L. et al., 2025. Efficacy of Janus kinase inhibitor combined with phototherapy in non\u2011segmental vitiligo: systematic review and meta\u2011analysis. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12777791\/<\/a><\/p>\n\n\n\n2. 308\u202fnm excimer laser combined with JAK inhibitors for adult localized non\u2011segmental vitiligo: a multicenter randomized controlled trial. https:\/\/pubmed.ncbi.nlm.nih.gov\/40682379\/<\/a><\/p>\n\n\n\n3. Zhou, B. et al., 2024. Combination therapy with baricitinib and narrowband ultraviolet B for active non\u2011segmental vitiligo: a retrospective controlled study. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11668684\/<\/a><\/p>\n\n\n\n4. Mumford, J. et al., 2023. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB\u2011UVB phototherapy. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10015970\/<\/a><\/p>\n\n\n\n5. Combination therapy with 308\u2011nm excimer laser, topical tacrolimus, and short\u2011term systemic corticosteroids for segmental vitiligo. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0190962215015108<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such […]<\/p>\n","protected":false},"author":4,"featured_media":6013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"Uncategorized<\/a>","rttpg_excerpt":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such…","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6049,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6013"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Phototherapy is an important and well-established part of vitiligo treatment. Narrowband ultraviolet B (NB-UVB) phototherapy has been used for many years and can help stimulate repigmentation when used consistently under medical supervision.<\/p>\n\n\n\n
EADV 2025 included research discussions on the role of phototherapy in segmental vitiligo, particularly in the context of newer treatments such as Janus kinase inhibitors. This highlights that phototherapy is still relevant, even as newer therapeutic options continue to emerge.<\/p>\n\n\n\n
Rather than replacing older approaches, modern vitiligo care often focuses on how different treatments can be combined, sequenced, or selected based on the individual patient. Phototherapy may still be especially useful in certain cases, depending on disease extent, location, access to treatment facilities, and patient preference.<\/p>\n\n\n\n
However, phototherapy also requires commitment and consistency. It often involves regular clinic visits over several months, which may not be practical for everyone due to work, study, travel, or family responsibilities. EADV discussions increasingly emphasise this real-world aspect, ensuring treatment plans are not only clinically effective but also realistic and sustainable for the patient\u2019s daily life.<\/p>\n\n\n\n
JAK Inhibitors and Targeted Treatment Discussions<\/strong><\/h2>\n\n\n\nOne of the most active areas in vitiligo research is targeted therapy, especially treatments linked to the JAK-STAT signalling pathway. JAK inhibitors have gained attention because they act on specific immune pathways involved in inflammatory and autoimmune skin conditions.<\/p>\n\n\n\n
EADV scientific programmes have included focused sessions on JAK inhibitors, reflecting their growing importance across dermatology. EADV 2025 updates also noted that JAK and TYK2 inhibitors are expanding in clinical use, although larger controlled studies are still needed to fully confirm long-term effectiveness, safety, and optimal use in different patient groups.<\/p>\n\n\n\n
In vitiligo, these treatments are particularly relevant because current options can be helpful but often produce slow or variable results. Targeted therapies raise important clinical questions around patient selection, treatment duration, combination with phototherapy, and long-term safety, which are all carefully discussed in specialist conferences before being applied in routine care.<\/p>\n\n\n\n
Long-Term Safety and Durability of Results<\/strong><\/h2>\n\n\n\nVitiligo care is not only about restoring pigmentation, but also about maintaining those results safely over time. This is why EADV sessions often focus on durability of response, relapse rates, maintenance therapy, and long-term safety of treatments.<\/p>\n\n\n\n
Research discussed around EADV meetings has explored longer-term outcomes for treatments such as topical ruxolitinib in vitiligo. This is important because vitiligo is usually a chronic condition, and short-term improvement does not always reflect how stable results will be over time.<\/p>\n\n\n\n
Clinicians need to understand whether repigmentation is maintained, whether vitiligo returns after stopping treatment, and whether ongoing therapy is required. They also consider side effects over longer use and how outcomes may differ across body sites such as the face, hands, and feet.<\/p>\n\n\n\n
Segmental Vitiligo and Special Patterns<\/strong><\/h2>\n\n\n\nVitiligo is not a single uniform condition in clinical practice. Segmental vitiligo typically affects one side or a specific segment of the body and often behaves differently from non-segmental vitiligo. It may stabilise earlier, but it can also respond differently to certain treatments.<\/p>\n\n\n\n
Because of these differences, EADV sessions often discuss tailored treatment strategies for segmental vitiligo. This can include phototherapy in selected cases, surgical options for stable disease in specialist centres, and newer medical treatments where appropriate.<\/p>\n\n\n\n
The key message is that classification matters. A dermatologist needs to assess the exact type of vitiligo, whether it is active or stable, its location, and how it is progressing before recommending a treatment plan. This helps ensure that patients receive realistic, individualised advice rather than general information that may not apply to their specific condition.<\/p>\n\n\n\n
Vitiligo in Children and Young People<\/strong><\/h2>\n\n\n\nVitiligo in children is an important area of discussion in dermatology. When a child develops vitiligo, it is common for parents to feel anxious about progression, treatment safety, school experiences, and the possibility of emotional impact or teasing.<\/p>\n\n\n\n
EADV sessions encourage clinicians to take a balanced approach, recognising that children are not simply small adults. Treatment decisions need to consider age, skin sensitivity, emotional wellbeing, and how practical it is for families to follow a treatment plan consistently over time.<\/p>\n\n\n\n
The psychological impact is also important. Children may not always express distress directly, but changes such as avoiding photographs, withdrawing socially, or becoming more self-conscious can indicate how the condition is affecting them. EADV discussions highlight the importance of looking beyond skin changes and considering the child\u2019s overall wellbeing.<\/p>\n\n\n\n
Skin of Colour and Vitiligo<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nVitiligo can affect people of all skin types, but its visibility often varies depending on natural skin tone. On darker skin, depigmented patches may appear more noticeable because the contrast between affected and unaffected skin is greater. This can sometimes increase social attention and emotional impact.<\/p>\n\n\n\n
EADV discussions on skin of colour, pigmentation, and treatment response are important because they highlight that vitiligo is not experienced in the same way by everyone. A small patch on the face, for example, may have a significant effect on confidence, identity, or cultural perception, even if it is medically limited in size.<\/p>\n\n\n\n
Skin type can also influence treatment choices and response. Dermatologists may need to consider risks such as post-inflammatory pigment changes, irritation, or uneven repigmentation, and ensure that advice on sun protection is clear and appropriate for all skin tones. EADV\u2019s international setting helps bring these perspectives together so care can be more inclusive, personalised, and realistic.<\/p>\n\n\n\n
Psychological Impact and Quality of Life<\/strong><\/h2>\n\n\n\nOne of the most important aspects of modern vitiligo care is its impact on quality of life. While vitiligo is not physically painful in most cases, it can have a significant emotional and psychological effect. Many people experience feelings such as self-consciousness, frustration, embarrassment, or exhaustion from repeatedly explaining their condition to others. These emotional responses can be just as important to address as the physical changes in skin appearance.<\/p>\n\n\n\n
\n- Emotional and Social Impact: <\/strong>Vitiligo can affect confidence and social comfort. Some individuals may feel hesitant in situations such as social gatherings, swimming, photography, dating, or professional environments due to concerns about appearance or attention.<\/li>\n\n\n\n
- Variation Between Individuals: <\/strong>The psychological impact of vitiligo is highly individual. Two people with the same level of skin involvement may experience it very differently, with one feeling unaffected and another experiencing significant emotional distress.<\/li>\n\n\n\n
- Importance of Patient Experience in Care: <\/strong>Modern dermatology emphasises patient-reported outcomes rather than focusing only on visible skin involvement. Understanding how vitiligo affects daily life helps clinicians provide more meaningful and personalised care.<\/li>\n\n\n\n
- Influence on Treatment Planning and Support: <\/strong>A patient\u2019s emotional wellbeing can influence treatment decisions, follow-up schedules, and support options. In some cases, psychological support or counselling may be an important part of overall management.<\/li>\n<\/ul>\n\n\n\n
Vitiligo care is not only about treating skin changes but also about understanding the emotional and social impact of the condition. Conferences and EADV discussions continue to reinforce the importance of quality of life in clinical decision-making. This approach helps dermatologists look beyond patch size and focus on how the condition affects each individual person. Ultimately, effective care should combine medical treatment with empathy, support, and attention to psychological wellbeing.<\/p>\n\n\n\n
Measuring Treatment Success<\/strong><\/h2>\n\n\n\nVitiligo treatment success is not always easy to define. Unlike some conditions where improvement is obvious, vitiligo often changes gradually and unevenly across different areas of the body, which can make progress harder to judge.<\/p>\n\n\n\n
Repigmentation may begin as small pigment spots around hair follicles, and it may appear earlier on the face compared with areas such as the hands or feet. Some areas may respond well to treatment while others show minimal change, even within the same person.<\/p>\n\n\n\n
EADV sessions often focus on how to measure outcomes more consistently, using tools such as clinical scoring systems, serial photographs, patient feedback, disease stability assessment, and quality-of-life measures. This helps create a clearer and more structured understanding of whether a treatment is truly working.<\/p>\n\n\n\n
For patients, this is important because unclear expectations can be frustrating. If you are simply told to \u201ccontinue treatment and wait,\u201d it may not be obvious what improvement should look like or when a change in approach should be considered. Better measurement supports clearer communication and more informed decisions between patients and clinicians, while also improving the quality and comparability of research studies.<\/p>\n\n\n\n
Combination Treatment Approaches<\/strong><\/h2>\n\n\n\nVitiligo treatment is often not based on a single long-term option, but rather on a combination of therapies tailored to the individual. Dermatologists may adjust treatment strategies depending on disease activity, response over time, and the areas of skin involved. This flexible approach allows care to be adapted rather than fixed, which is particularly important in a condition that can behave unpredictably. EADV sessions frequently explore how these combinations can be used effectively in real clinical practice.<\/p>\n\n\n\n
\n- Using Topical and Light-Based Therapies Together: <\/strong>A common approach involves combining topical treatments with phototherapy. Light-based therapy may help stimulate pigment production, while topical treatments can help reduce inflammation and support repigmentation.<\/li>\n\n\n\n
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n
- Balancing Benefits and Practical Challenges: <\/strong>While combination therapy can be effective, it also needs careful planning. More treatments do not always mean better results and may increase cost, side effects, or daily treatment burden for the patient.<\/li>\n\n\n\n
- Personalised Treatment Selection: <\/strong>The most effective combination is not necessarily the most intensive one. It is the approach that best fits the patient\u2019s condition, lifestyle, safety considerations, and personal treatment goals.<\/li>\n<\/ul>\n\n\n\n
Combination treatment approaches in vitiligo care highlight the importance of flexibility and personalisation in dermatology. EADV discussions continue to show that thoughtful pairing of therapies can improve outcomes when used appropriately. However, careful planning is essential to avoid unnecessary complexity or treatment burden. Ultimately, the best care is tailored to the individual, balancing effectiveness, safety, and long-term manageability.<\/p>\n\n\n\n
How EADV Sessions Influence Clinical Practice<\/strong><\/h2>\n\n\n\nEADV congress sessions do not usually change clinical practice overnight, but they do play an important role in shaping how dermatologists think, discuss, and refine patient care. A clinician may attend a session on new research and later apply that learning when reviewing treatment plans, advising patients, or deciding when specialist referral is needed.<\/p>\n\n\n\n
These sessions influence practice in several ways. They highlight emerging treatments, clarify where evidence is strong, and identify areas where more research is still needed. They also encourage doctors to focus more on patient experience and quality of life, not just clinical trial results.<\/p>\n\n\n\n
Over time, this collective learning can influence guidelines, prescribing patterns, medical education, and how clinicians communicate with patients. For example, if research consistently highlights the importance of early treatment in active vitiligo, clinicians may become more attentive to early signs of progression and intervene sooner.<\/p>\n\n\n\n
This is how conference evidence gradually translates into real-world care. It moves from presentations and discussions at EADV into everyday consultations, helping improve both medical decision-making and patient understanding.<\/p>\n\n\n\n
What Patients Can Take from EADV Vitiligo Discussions<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nIf you are living with vitiligo, you do not need to follow every scientific detail presented at EADV. However, it can be helpful to understand the general direction that modern care is taking.<\/p>\n\n\n\n
Vitiligo treatment is becoming more personalised, with greater focus on immune mechanisms, disease activity, timing of intervention, quality of life, and long-term management rather than short-term cosmetic change alone.<\/p>\n\n\n\n
At the same time, newer targeted treatments are emerging, but this does not mean older approaches have become irrelevant. Topical treatments, phototherapy, psychological support, camouflage techniques, and lifestyle guidance still play an important role depending on the individual\u2019s needs and condition.<\/p>\n\n\n\n
It is also important to be cautious with online information, as vitiligo can be emotionally challenging and may attract exaggerated claims or unrealistic promises. EADV discussions are valuable because they are based on scientific evidence, clinical experience, and peer-reviewed research rather than anecdotal reports or marketing claims.<\/p>\n\n\n\n
Future Directions in Vitiligo Research<\/strong><\/h2>\n\n\n\nThe future of vitiligo research is likely to focus on more targeted, personalised, and measurable treatment approaches. Researchers are continuing to explore immune pathways, genetic influences, biomarkers, relapse prevention, maintenance strategies, and combination therapies. Recent reviews summarising advances between 2020 and 2025 show how active and rapidly evolving this field has become.<\/p>\n\n\n\n
However, not every new development will automatically become standard care. Some treatments may require more long-term safety data, while others may only be effective in specific patient groups. Practical factors such as access, cost, and availability will also influence how widely new therapies are used in real-world settings.<\/p>\n\n\n\n
Despite these challenges, the overall direction is encouraging. Vitiligo is receiving significantly more scientific attention than in the past, and there is a stronger focus on patient-reported outcomes, quality of life, and shared decision-making alongside clinical results.<\/p>\n\n\n\n
EADV sessions play an important role in bringing these elements together. They provide a platform where scientific research, clinical experience, and patient perspectives can be discussed and refined, helping shape the future direction of vitiligo care.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n1. What is the main focus of EADV vitiligo sessions?
<\/strong>EADV vitiligo sessions focus on advancing understanding of Vitiligo through research updates, clinical guidelines, treatment innovations, and real-world patient care strategies.<\/p>\n\n\n\n2. Why is vitiligo discussed at European Academy of Dermatology and Venereology meetings?
<\/strong>Because vitiligo is a complex immune-mediated condition, EADV brings together experts to share evidence, improve treatment approaches, and address both medical and psychological aspects of care.<\/p>\n\n\n\n3. What new treatments are discussed in EADV vitiligo sessions?
<\/strong>Sessions often cover topical therapies, phototherapy, and newer targeted treatments such as JAK pathway-based approaches, including discussion of JAK inhibitors.<\/p>\n\n\n\n4. Do EADV sessions focus only on medical treatments?
<\/strong>No. They also focus on psychological impact, quality of life, disease classification, patient experience, and long-term management strategies for vitiligo.<\/p>\n\n\n\n5. How is vitiligo classified in EADV discussions?
<\/strong>Dermatologists discuss whether vitiligo is segmental or non-segmental, stable or active, and how different patterns affect treatment response and outcomes.<\/p>\n\n\n\n6. What role does phototherapy play in vitiligo treatment?
<\/strong>Phototherapy, especially narrowband UVB, remains an important treatment option and is often combined with topical or newer therapies to improve repigmentation.<\/p>\n\n\n\n7. Are JAK inhibitors a cure for vitiligo?
<\/strong>No. JAK inhibitors are promising targeted therapies that may help repigmentation, but they are not a cure and require more long-term safety and effectiveness data.<\/p>\n\n\n\n8. How do EADV sessions address psychological impact?
<\/strong>They highlight that vitiligo can significantly affect confidence, social life, and emotional wellbeing, and encourage integrating psychological support into treatment planning.<\/p>\n\n\n\n9. Do all patients respond the same way to vitiligo treatments?
<\/strong>No. Treatment response varies depending on skin type, disease activity, location of patches, and individual immune response, which is why personalised care is emphasised.<\/p>\n\n\n\n10. What is the future direction of vitiligo research discussed at EADV?
<\/strong>Future research focuses on targeted therapies, immune pathways, relapse prevention, combination treatments, and improving long-term outcomes while prioritising patient quality of life.<\/p>\n\n\n\nFinal Thoughts: The Evolving Understanding of Vitiligo Care at EADV<\/strong><\/h2>\n\n\n\nEADV vitiligo sessions highlight how rapidly this field is evolving, moving beyond simple repigmentation approaches towards a more complete understanding of Vitiligo as an immune-mediated condition. These discussions bring together new research, emerging therapies such as targeted treatments, and long-standing approaches like topical therapy and phototherapy, while also placing strong emphasis on quality of life, psychological wellbeing, and personalised care.<\/p>\n\n\n\n
The overall direction is clear: vitiligo management is becoming more individualised, evidence-driven, and focused on long-term outcomes rather than short-term results alone. If you\u2019re looking for Vitiligo treatment in London<\/a>, you can reach out to us at the London Dermatology Centre to book a consultation with one of our specialists.<\/p>\n\n\n\nReferences:<\/strong><\/h2>\n\n\n\n1. Shuaib, L. et al., 2025. Efficacy of Janus kinase inhibitor combined with phototherapy in non\u2011segmental vitiligo: systematic review and meta\u2011analysis. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12777791\/<\/a><\/p>\n\n\n\n2. 308\u202fnm excimer laser combined with JAK inhibitors for adult localized non\u2011segmental vitiligo: a multicenter randomized controlled trial. https:\/\/pubmed.ncbi.nlm.nih.gov\/40682379\/<\/a><\/p>\n\n\n\n3. Zhou, B. et al., 2024. Combination therapy with baricitinib and narrowband ultraviolet B for active non\u2011segmental vitiligo: a retrospective controlled study. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11668684\/<\/a><\/p>\n\n\n\n4. Mumford, J. et al., 2023. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB\u2011UVB phototherapy. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10015970\/<\/a><\/p>\n\n\n\n5. Combination therapy with 308\u2011nm excimer laser, topical tacrolimus, and short\u2011term systemic corticosteroids for segmental vitiligo. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0190962215015108<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such […]<\/p>\n","protected":false},"author":4,"featured_media":6013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"Uncategorized<\/a>","rttpg_excerpt":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such…","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6049,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6013"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Vitiligo care is not only about restoring pigmentation, but also about maintaining those results safely over time. This is why EADV sessions often focus on durability of response, relapse rates, maintenance therapy, and long-term safety of treatments.<\/p>\n\n\n\n
Research discussed around EADV meetings has explored longer-term outcomes for treatments such as topical ruxolitinib in vitiligo. This is important because vitiligo is usually a chronic condition, and short-term improvement does not always reflect how stable results will be over time.<\/p>\n\n\n\n
Clinicians need to understand whether repigmentation is maintained, whether vitiligo returns after stopping treatment, and whether ongoing therapy is required. They also consider side effects over longer use and how outcomes may differ across body sites such as the face, hands, and feet.<\/p>\n\n\n\n
Segmental Vitiligo and Special Patterns<\/strong><\/h2>\n\n\n\nVitiligo is not a single uniform condition in clinical practice. Segmental vitiligo typically affects one side or a specific segment of the body and often behaves differently from non-segmental vitiligo. It may stabilise earlier, but it can also respond differently to certain treatments.<\/p>\n\n\n\n
Because of these differences, EADV sessions often discuss tailored treatment strategies for segmental vitiligo. This can include phototherapy in selected cases, surgical options for stable disease in specialist centres, and newer medical treatments where appropriate.<\/p>\n\n\n\n
The key message is that classification matters. A dermatologist needs to assess the exact type of vitiligo, whether it is active or stable, its location, and how it is progressing before recommending a treatment plan. This helps ensure that patients receive realistic, individualised advice rather than general information that may not apply to their specific condition.<\/p>\n\n\n\n
Vitiligo in Children and Young People<\/strong><\/h2>\n\n\n\nVitiligo in children is an important area of discussion in dermatology. When a child develops vitiligo, it is common for parents to feel anxious about progression, treatment safety, school experiences, and the possibility of emotional impact or teasing.<\/p>\n\n\n\n
EADV sessions encourage clinicians to take a balanced approach, recognising that children are not simply small adults. Treatment decisions need to consider age, skin sensitivity, emotional wellbeing, and how practical it is for families to follow a treatment plan consistently over time.<\/p>\n\n\n\n
The psychological impact is also important. Children may not always express distress directly, but changes such as avoiding photographs, withdrawing socially, or becoming more self-conscious can indicate how the condition is affecting them. EADV discussions highlight the importance of looking beyond skin changes and considering the child\u2019s overall wellbeing.<\/p>\n\n\n\n
Skin of Colour and Vitiligo<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nVitiligo can affect people of all skin types, but its visibility often varies depending on natural skin tone. On darker skin, depigmented patches may appear more noticeable because the contrast between affected and unaffected skin is greater. This can sometimes increase social attention and emotional impact.<\/p>\n\n\n\n
EADV discussions on skin of colour, pigmentation, and treatment response are important because they highlight that vitiligo is not experienced in the same way by everyone. A small patch on the face, for example, may have a significant effect on confidence, identity, or cultural perception, even if it is medically limited in size.<\/p>\n\n\n\n
Skin type can also influence treatment choices and response. Dermatologists may need to consider risks such as post-inflammatory pigment changes, irritation, or uneven repigmentation, and ensure that advice on sun protection is clear and appropriate for all skin tones. EADV\u2019s international setting helps bring these perspectives together so care can be more inclusive, personalised, and realistic.<\/p>\n\n\n\n
Psychological Impact and Quality of Life<\/strong><\/h2>\n\n\n\nOne of the most important aspects of modern vitiligo care is its impact on quality of life. While vitiligo is not physically painful in most cases, it can have a significant emotional and psychological effect. Many people experience feelings such as self-consciousness, frustration, embarrassment, or exhaustion from repeatedly explaining their condition to others. These emotional responses can be just as important to address as the physical changes in skin appearance.<\/p>\n\n\n\n
\n- Emotional and Social Impact: <\/strong>Vitiligo can affect confidence and social comfort. Some individuals may feel hesitant in situations such as social gatherings, swimming, photography, dating, or professional environments due to concerns about appearance or attention.<\/li>\n\n\n\n
- Variation Between Individuals: <\/strong>The psychological impact of vitiligo is highly individual. Two people with the same level of skin involvement may experience it very differently, with one feeling unaffected and another experiencing significant emotional distress.<\/li>\n\n\n\n
- Importance of Patient Experience in Care: <\/strong>Modern dermatology emphasises patient-reported outcomes rather than focusing only on visible skin involvement. Understanding how vitiligo affects daily life helps clinicians provide more meaningful and personalised care.<\/li>\n\n\n\n
- Influence on Treatment Planning and Support: <\/strong>A patient\u2019s emotional wellbeing can influence treatment decisions, follow-up schedules, and support options. In some cases, psychological support or counselling may be an important part of overall management.<\/li>\n<\/ul>\n\n\n\n
Vitiligo care is not only about treating skin changes but also about understanding the emotional and social impact of the condition. Conferences and EADV discussions continue to reinforce the importance of quality of life in clinical decision-making. This approach helps dermatologists look beyond patch size and focus on how the condition affects each individual person. Ultimately, effective care should combine medical treatment with empathy, support, and attention to psychological wellbeing.<\/p>\n\n\n\n
Measuring Treatment Success<\/strong><\/h2>\n\n\n\nVitiligo treatment success is not always easy to define. Unlike some conditions where improvement is obvious, vitiligo often changes gradually and unevenly across different areas of the body, which can make progress harder to judge.<\/p>\n\n\n\n
Repigmentation may begin as small pigment spots around hair follicles, and it may appear earlier on the face compared with areas such as the hands or feet. Some areas may respond well to treatment while others show minimal change, even within the same person.<\/p>\n\n\n\n
EADV sessions often focus on how to measure outcomes more consistently, using tools such as clinical scoring systems, serial photographs, patient feedback, disease stability assessment, and quality-of-life measures. This helps create a clearer and more structured understanding of whether a treatment is truly working.<\/p>\n\n\n\n
For patients, this is important because unclear expectations can be frustrating. If you are simply told to \u201ccontinue treatment and wait,\u201d it may not be obvious what improvement should look like or when a change in approach should be considered. Better measurement supports clearer communication and more informed decisions between patients and clinicians, while also improving the quality and comparability of research studies.<\/p>\n\n\n\n
Combination Treatment Approaches<\/strong><\/h2>\n\n\n\nVitiligo treatment is often not based on a single long-term option, but rather on a combination of therapies tailored to the individual. Dermatologists may adjust treatment strategies depending on disease activity, response over time, and the areas of skin involved. This flexible approach allows care to be adapted rather than fixed, which is particularly important in a condition that can behave unpredictably. EADV sessions frequently explore how these combinations can be used effectively in real clinical practice.<\/p>\n\n\n\n
\n- Using Topical and Light-Based Therapies Together: <\/strong>A common approach involves combining topical treatments with phototherapy. Light-based therapy may help stimulate pigment production, while topical treatments can help reduce inflammation and support repigmentation.<\/li>\n\n\n\n
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n
- Balancing Benefits and Practical Challenges: <\/strong>While combination therapy can be effective, it also needs careful planning. More treatments do not always mean better results and may increase cost, side effects, or daily treatment burden for the patient.<\/li>\n\n\n\n
- Personalised Treatment Selection: <\/strong>The most effective combination is not necessarily the most intensive one. It is the approach that best fits the patient\u2019s condition, lifestyle, safety considerations, and personal treatment goals.<\/li>\n<\/ul>\n\n\n\n
Combination treatment approaches in vitiligo care highlight the importance of flexibility and personalisation in dermatology. EADV discussions continue to show that thoughtful pairing of therapies can improve outcomes when used appropriately. However, careful planning is essential to avoid unnecessary complexity or treatment burden. Ultimately, the best care is tailored to the individual, balancing effectiveness, safety, and long-term manageability.<\/p>\n\n\n\n
How EADV Sessions Influence Clinical Practice<\/strong><\/h2>\n\n\n\nEADV congress sessions do not usually change clinical practice overnight, but they do play an important role in shaping how dermatologists think, discuss, and refine patient care. A clinician may attend a session on new research and later apply that learning when reviewing treatment plans, advising patients, or deciding when specialist referral is needed.<\/p>\n\n\n\n
These sessions influence practice in several ways. They highlight emerging treatments, clarify where evidence is strong, and identify areas where more research is still needed. They also encourage doctors to focus more on patient experience and quality of life, not just clinical trial results.<\/p>\n\n\n\n
Over time, this collective learning can influence guidelines, prescribing patterns, medical education, and how clinicians communicate with patients. For example, if research consistently highlights the importance of early treatment in active vitiligo, clinicians may become more attentive to early signs of progression and intervene sooner.<\/p>\n\n\n\n
This is how conference evidence gradually translates into real-world care. It moves from presentations and discussions at EADV into everyday consultations, helping improve both medical decision-making and patient understanding.<\/p>\n\n\n\n
What Patients Can Take from EADV Vitiligo Discussions<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nIf you are living with vitiligo, you do not need to follow every scientific detail presented at EADV. However, it can be helpful to understand the general direction that modern care is taking.<\/p>\n\n\n\n
Vitiligo treatment is becoming more personalised, with greater focus on immune mechanisms, disease activity, timing of intervention, quality of life, and long-term management rather than short-term cosmetic change alone.<\/p>\n\n\n\n
At the same time, newer targeted treatments are emerging, but this does not mean older approaches have become irrelevant. Topical treatments, phototherapy, psychological support, camouflage techniques, and lifestyle guidance still play an important role depending on the individual\u2019s needs and condition.<\/p>\n\n\n\n
It is also important to be cautious with online information, as vitiligo can be emotionally challenging and may attract exaggerated claims or unrealistic promises. EADV discussions are valuable because they are based on scientific evidence, clinical experience, and peer-reviewed research rather than anecdotal reports or marketing claims.<\/p>\n\n\n\n
Future Directions in Vitiligo Research<\/strong><\/h2>\n\n\n\nThe future of vitiligo research is likely to focus on more targeted, personalised, and measurable treatment approaches. Researchers are continuing to explore immune pathways, genetic influences, biomarkers, relapse prevention, maintenance strategies, and combination therapies. Recent reviews summarising advances between 2020 and 2025 show how active and rapidly evolving this field has become.<\/p>\n\n\n\n
However, not every new development will automatically become standard care. Some treatments may require more long-term safety data, while others may only be effective in specific patient groups. Practical factors such as access, cost, and availability will also influence how widely new therapies are used in real-world settings.<\/p>\n\n\n\n
Despite these challenges, the overall direction is encouraging. Vitiligo is receiving significantly more scientific attention than in the past, and there is a stronger focus on patient-reported outcomes, quality of life, and shared decision-making alongside clinical results.<\/p>\n\n\n\n
EADV sessions play an important role in bringing these elements together. They provide a platform where scientific research, clinical experience, and patient perspectives can be discussed and refined, helping shape the future direction of vitiligo care.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n1. What is the main focus of EADV vitiligo sessions?
<\/strong>EADV vitiligo sessions focus on advancing understanding of Vitiligo through research updates, clinical guidelines, treatment innovations, and real-world patient care strategies.<\/p>\n\n\n\n2. Why is vitiligo discussed at European Academy of Dermatology and Venereology meetings?
<\/strong>Because vitiligo is a complex immune-mediated condition, EADV brings together experts to share evidence, improve treatment approaches, and address both medical and psychological aspects of care.<\/p>\n\n\n\n3. What new treatments are discussed in EADV vitiligo sessions?
<\/strong>Sessions often cover topical therapies, phototherapy, and newer targeted treatments such as JAK pathway-based approaches, including discussion of JAK inhibitors.<\/p>\n\n\n\n4. Do EADV sessions focus only on medical treatments?
<\/strong>No. They also focus on psychological impact, quality of life, disease classification, patient experience, and long-term management strategies for vitiligo.<\/p>\n\n\n\n5. How is vitiligo classified in EADV discussions?
<\/strong>Dermatologists discuss whether vitiligo is segmental or non-segmental, stable or active, and how different patterns affect treatment response and outcomes.<\/p>\n\n\n\n6. What role does phototherapy play in vitiligo treatment?
<\/strong>Phototherapy, especially narrowband UVB, remains an important treatment option and is often combined with topical or newer therapies to improve repigmentation.<\/p>\n\n\n\n7. Are JAK inhibitors a cure for vitiligo?
<\/strong>No. JAK inhibitors are promising targeted therapies that may help repigmentation, but they are not a cure and require more long-term safety and effectiveness data.<\/p>\n\n\n\n8. How do EADV sessions address psychological impact?
<\/strong>They highlight that vitiligo can significantly affect confidence, social life, and emotional wellbeing, and encourage integrating psychological support into treatment planning.<\/p>\n\n\n\n9. Do all patients respond the same way to vitiligo treatments?
<\/strong>No. Treatment response varies depending on skin type, disease activity, location of patches, and individual immune response, which is why personalised care is emphasised.<\/p>\n\n\n\n10. What is the future direction of vitiligo research discussed at EADV?
<\/strong>Future research focuses on targeted therapies, immune pathways, relapse prevention, combination treatments, and improving long-term outcomes while prioritising patient quality of life.<\/p>\n\n\n\nFinal Thoughts: The Evolving Understanding of Vitiligo Care at EADV<\/strong><\/h2>\n\n\n\nEADV vitiligo sessions highlight how rapidly this field is evolving, moving beyond simple repigmentation approaches towards a more complete understanding of Vitiligo as an immune-mediated condition. These discussions bring together new research, emerging therapies such as targeted treatments, and long-standing approaches like topical therapy and phototherapy, while also placing strong emphasis on quality of life, psychological wellbeing, and personalised care.<\/p>\n\n\n\n
The overall direction is clear: vitiligo management is becoming more individualised, evidence-driven, and focused on long-term outcomes rather than short-term results alone. If you\u2019re looking for Vitiligo treatment in London<\/a>, you can reach out to us at the London Dermatology Centre to book a consultation with one of our specialists.<\/p>\n\n\n\nReferences:<\/strong><\/h2>\n\n\n\n1. Shuaib, L. et al., 2025. Efficacy of Janus kinase inhibitor combined with phototherapy in non\u2011segmental vitiligo: systematic review and meta\u2011analysis. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12777791\/<\/a><\/p>\n\n\n\n2. 308\u202fnm excimer laser combined with JAK inhibitors for adult localized non\u2011segmental vitiligo: a multicenter randomized controlled trial. https:\/\/pubmed.ncbi.nlm.nih.gov\/40682379\/<\/a><\/p>\n\n\n\n3. Zhou, B. et al., 2024. Combination therapy with baricitinib and narrowband ultraviolet B for active non\u2011segmental vitiligo: a retrospective controlled study. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11668684\/<\/a><\/p>\n\n\n\n4. Mumford, J. et al., 2023. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB\u2011UVB phototherapy. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10015970\/<\/a><\/p>\n\n\n\n5. Combination therapy with 308\u2011nm excimer laser, topical tacrolimus, and short\u2011term systemic corticosteroids for segmental vitiligo. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0190962215015108<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such […]<\/p>\n","protected":false},"author":4,"featured_media":6013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"Uncategorized<\/a>","rttpg_excerpt":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such…","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6049,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6013"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Vitiligo in children is an important area of discussion in dermatology. When a child develops vitiligo, it is common for parents to feel anxious about progression, treatment safety, school experiences, and the possibility of emotional impact or teasing.<\/p>\n\n\n\n
EADV sessions encourage clinicians to take a balanced approach, recognising that children are not simply small adults. Treatment decisions need to consider age, skin sensitivity, emotional wellbeing, and how practical it is for families to follow a treatment plan consistently over time.<\/p>\n\n\n\n
The psychological impact is also important. Children may not always express distress directly, but changes such as avoiding photographs, withdrawing socially, or becoming more self-conscious can indicate how the condition is affecting them. EADV discussions highlight the importance of looking beyond skin changes and considering the child\u2019s overall wellbeing.<\/p>\n\n\n\n
Skin of Colour and Vitiligo<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nVitiligo can affect people of all skin types, but its visibility often varies depending on natural skin tone. On darker skin, depigmented patches may appear more noticeable because the contrast between affected and unaffected skin is greater. This can sometimes increase social attention and emotional impact.<\/p>\n\n\n\n
EADV discussions on skin of colour, pigmentation, and treatment response are important because they highlight that vitiligo is not experienced in the same way by everyone. A small patch on the face, for example, may have a significant effect on confidence, identity, or cultural perception, even if it is medically limited in size.<\/p>\n\n\n\n
Skin type can also influence treatment choices and response. Dermatologists may need to consider risks such as post-inflammatory pigment changes, irritation, or uneven repigmentation, and ensure that advice on sun protection is clear and appropriate for all skin tones. EADV\u2019s international setting helps bring these perspectives together so care can be more inclusive, personalised, and realistic.<\/p>\n\n\n\n
Psychological Impact and Quality of Life<\/strong><\/h2>\n\n\n\nOne of the most important aspects of modern vitiligo care is its impact on quality of life. While vitiligo is not physically painful in most cases, it can have a significant emotional and psychological effect. Many people experience feelings such as self-consciousness, frustration, embarrassment, or exhaustion from repeatedly explaining their condition to others. These emotional responses can be just as important to address as the physical changes in skin appearance.<\/p>\n\n\n\n
\n- Emotional and Social Impact: <\/strong>Vitiligo can affect confidence and social comfort. Some individuals may feel hesitant in situations such as social gatherings, swimming, photography, dating, or professional environments due to concerns about appearance or attention.<\/li>\n\n\n\n
- Variation Between Individuals: <\/strong>The psychological impact of vitiligo is highly individual. Two people with the same level of skin involvement may experience it very differently, with one feeling unaffected and another experiencing significant emotional distress.<\/li>\n\n\n\n
- Importance of Patient Experience in Care: <\/strong>Modern dermatology emphasises patient-reported outcomes rather than focusing only on visible skin involvement. Understanding how vitiligo affects daily life helps clinicians provide more meaningful and personalised care.<\/li>\n\n\n\n
- Influence on Treatment Planning and Support: <\/strong>A patient\u2019s emotional wellbeing can influence treatment decisions, follow-up schedules, and support options. In some cases, psychological support or counselling may be an important part of overall management.<\/li>\n<\/ul>\n\n\n\n
Vitiligo care is not only about treating skin changes but also about understanding the emotional and social impact of the condition. Conferences and EADV discussions continue to reinforce the importance of quality of life in clinical decision-making. This approach helps dermatologists look beyond patch size and focus on how the condition affects each individual person. Ultimately, effective care should combine medical treatment with empathy, support, and attention to psychological wellbeing.<\/p>\n\n\n\n
Measuring Treatment Success<\/strong><\/h2>\n\n\n\nVitiligo treatment success is not always easy to define. Unlike some conditions where improvement is obvious, vitiligo often changes gradually and unevenly across different areas of the body, which can make progress harder to judge.<\/p>\n\n\n\n
Repigmentation may begin as small pigment spots around hair follicles, and it may appear earlier on the face compared with areas such as the hands or feet. Some areas may respond well to treatment while others show minimal change, even within the same person.<\/p>\n\n\n\n
EADV sessions often focus on how to measure outcomes more consistently, using tools such as clinical scoring systems, serial photographs, patient feedback, disease stability assessment, and quality-of-life measures. This helps create a clearer and more structured understanding of whether a treatment is truly working.<\/p>\n\n\n\n
For patients, this is important because unclear expectations can be frustrating. If you are simply told to \u201ccontinue treatment and wait,\u201d it may not be obvious what improvement should look like or when a change in approach should be considered. Better measurement supports clearer communication and more informed decisions between patients and clinicians, while also improving the quality and comparability of research studies.<\/p>\n\n\n\n
Combination Treatment Approaches<\/strong><\/h2>\n\n\n\nVitiligo treatment is often not based on a single long-term option, but rather on a combination of therapies tailored to the individual. Dermatologists may adjust treatment strategies depending on disease activity, response over time, and the areas of skin involved. This flexible approach allows care to be adapted rather than fixed, which is particularly important in a condition that can behave unpredictably. EADV sessions frequently explore how these combinations can be used effectively in real clinical practice.<\/p>\n\n\n\n
\n- Using Topical and Light-Based Therapies Together: <\/strong>A common approach involves combining topical treatments with phototherapy. Light-based therapy may help stimulate pigment production, while topical treatments can help reduce inflammation and support repigmentation.<\/li>\n\n\n\n
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n
- Balancing Benefits and Practical Challenges: <\/strong>While combination therapy can be effective, it also needs careful planning. More treatments do not always mean better results and may increase cost, side effects, or daily treatment burden for the patient.<\/li>\n\n\n\n
- Personalised Treatment Selection: <\/strong>The most effective combination is not necessarily the most intensive one. It is the approach that best fits the patient\u2019s condition, lifestyle, safety considerations, and personal treatment goals.<\/li>\n<\/ul>\n\n\n\n
Combination treatment approaches in vitiligo care highlight the importance of flexibility and personalisation in dermatology. EADV discussions continue to show that thoughtful pairing of therapies can improve outcomes when used appropriately. However, careful planning is essential to avoid unnecessary complexity or treatment burden. Ultimately, the best care is tailored to the individual, balancing effectiveness, safety, and long-term manageability.<\/p>\n\n\n\n
How EADV Sessions Influence Clinical Practice<\/strong><\/h2>\n\n\n\nEADV congress sessions do not usually change clinical practice overnight, but they do play an important role in shaping how dermatologists think, discuss, and refine patient care. A clinician may attend a session on new research and later apply that learning when reviewing treatment plans, advising patients, or deciding when specialist referral is needed.<\/p>\n\n\n\n
These sessions influence practice in several ways. They highlight emerging treatments, clarify where evidence is strong, and identify areas where more research is still needed. They also encourage doctors to focus more on patient experience and quality of life, not just clinical trial results.<\/p>\n\n\n\n
Over time, this collective learning can influence guidelines, prescribing patterns, medical education, and how clinicians communicate with patients. For example, if research consistently highlights the importance of early treatment in active vitiligo, clinicians may become more attentive to early signs of progression and intervene sooner.<\/p>\n\n\n\n
This is how conference evidence gradually translates into real-world care. It moves from presentations and discussions at EADV into everyday consultations, helping improve both medical decision-making and patient understanding.<\/p>\n\n\n\n
What Patients Can Take from EADV Vitiligo Discussions<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nIf you are living with vitiligo, you do not need to follow every scientific detail presented at EADV. However, it can be helpful to understand the general direction that modern care is taking.<\/p>\n\n\n\n
Vitiligo treatment is becoming more personalised, with greater focus on immune mechanisms, disease activity, timing of intervention, quality of life, and long-term management rather than short-term cosmetic change alone.<\/p>\n\n\n\n
At the same time, newer targeted treatments are emerging, but this does not mean older approaches have become irrelevant. Topical treatments, phototherapy, psychological support, camouflage techniques, and lifestyle guidance still play an important role depending on the individual\u2019s needs and condition.<\/p>\n\n\n\n
It is also important to be cautious with online information, as vitiligo can be emotionally challenging and may attract exaggerated claims or unrealistic promises. EADV discussions are valuable because they are based on scientific evidence, clinical experience, and peer-reviewed research rather than anecdotal reports or marketing claims.<\/p>\n\n\n\n
Future Directions in Vitiligo Research<\/strong><\/h2>\n\n\n\nThe future of vitiligo research is likely to focus on more targeted, personalised, and measurable treatment approaches. Researchers are continuing to explore immune pathways, genetic influences, biomarkers, relapse prevention, maintenance strategies, and combination therapies. Recent reviews summarising advances between 2020 and 2025 show how active and rapidly evolving this field has become.<\/p>\n\n\n\n
However, not every new development will automatically become standard care. Some treatments may require more long-term safety data, while others may only be effective in specific patient groups. Practical factors such as access, cost, and availability will also influence how widely new therapies are used in real-world settings.<\/p>\n\n\n\n
Despite these challenges, the overall direction is encouraging. Vitiligo is receiving significantly more scientific attention than in the past, and there is a stronger focus on patient-reported outcomes, quality of life, and shared decision-making alongside clinical results.<\/p>\n\n\n\n
EADV sessions play an important role in bringing these elements together. They provide a platform where scientific research, clinical experience, and patient perspectives can be discussed and refined, helping shape the future direction of vitiligo care.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n1. What is the main focus of EADV vitiligo sessions?
<\/strong>EADV vitiligo sessions focus on advancing understanding of Vitiligo through research updates, clinical guidelines, treatment innovations, and real-world patient care strategies.<\/p>\n\n\n\n2. Why is vitiligo discussed at European Academy of Dermatology and Venereology meetings?
<\/strong>Because vitiligo is a complex immune-mediated condition, EADV brings together experts to share evidence, improve treatment approaches, and address both medical and psychological aspects of care.<\/p>\n\n\n\n3. What new treatments are discussed in EADV vitiligo sessions?
<\/strong>Sessions often cover topical therapies, phototherapy, and newer targeted treatments such as JAK pathway-based approaches, including discussion of JAK inhibitors.<\/p>\n\n\n\n4. Do EADV sessions focus only on medical treatments?
<\/strong>No. They also focus on psychological impact, quality of life, disease classification, patient experience, and long-term management strategies for vitiligo.<\/p>\n\n\n\n5. How is vitiligo classified in EADV discussions?
<\/strong>Dermatologists discuss whether vitiligo is segmental or non-segmental, stable or active, and how different patterns affect treatment response and outcomes.<\/p>\n\n\n\n6. What role does phototherapy play in vitiligo treatment?
<\/strong>Phototherapy, especially narrowband UVB, remains an important treatment option and is often combined with topical or newer therapies to improve repigmentation.<\/p>\n\n\n\n7. Are JAK inhibitors a cure for vitiligo?
<\/strong>No. JAK inhibitors are promising targeted therapies that may help repigmentation, but they are not a cure and require more long-term safety and effectiveness data.<\/p>\n\n\n\n8. How do EADV sessions address psychological impact?
<\/strong>They highlight that vitiligo can significantly affect confidence, social life, and emotional wellbeing, and encourage integrating psychological support into treatment planning.<\/p>\n\n\n\n9. Do all patients respond the same way to vitiligo treatments?
<\/strong>No. Treatment response varies depending on skin type, disease activity, location of patches, and individual immune response, which is why personalised care is emphasised.<\/p>\n\n\n\n10. What is the future direction of vitiligo research discussed at EADV?
<\/strong>Future research focuses on targeted therapies, immune pathways, relapse prevention, combination treatments, and improving long-term outcomes while prioritising patient quality of life.<\/p>\n\n\n\nFinal Thoughts: The Evolving Understanding of Vitiligo Care at EADV<\/strong><\/h2>\n\n\n\nEADV vitiligo sessions highlight how rapidly this field is evolving, moving beyond simple repigmentation approaches towards a more complete understanding of Vitiligo as an immune-mediated condition. These discussions bring together new research, emerging therapies such as targeted treatments, and long-standing approaches like topical therapy and phototherapy, while also placing strong emphasis on quality of life, psychological wellbeing, and personalised care.<\/p>\n\n\n\n
The overall direction is clear: vitiligo management is becoming more individualised, evidence-driven, and focused on long-term outcomes rather than short-term results alone. If you\u2019re looking for Vitiligo treatment in London<\/a>, you can reach out to us at the London Dermatology Centre to book a consultation with one of our specialists.<\/p>\n\n\n\nReferences:<\/strong><\/h2>\n\n\n\n1. Shuaib, L. et al., 2025. Efficacy of Janus kinase inhibitor combined with phototherapy in non\u2011segmental vitiligo: systematic review and meta\u2011analysis. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12777791\/<\/a><\/p>\n\n\n\n2. 308\u202fnm excimer laser combined with JAK inhibitors for adult localized non\u2011segmental vitiligo: a multicenter randomized controlled trial. https:\/\/pubmed.ncbi.nlm.nih.gov\/40682379\/<\/a><\/p>\n\n\n\n3. Zhou, B. et al., 2024. Combination therapy with baricitinib and narrowband ultraviolet B for active non\u2011segmental vitiligo: a retrospective controlled study. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11668684\/<\/a><\/p>\n\n\n\n4. Mumford, J. et al., 2023. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB\u2011UVB phototherapy. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10015970\/<\/a><\/p>\n\n\n\n5. Combination therapy with 308\u2011nm excimer laser, topical tacrolimus, and short\u2011term systemic corticosteroids for segmental vitiligo. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0190962215015108<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such […]<\/p>\n","protected":false},"author":4,"featured_media":6013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"Uncategorized<\/a>","rttpg_excerpt":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such…","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6049,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6013"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/figure>\n\n\n\nVitiligo can affect people of all skin types, but its visibility often varies depending on natural skin tone. On darker skin, depigmented patches may appear more noticeable because the contrast between affected and unaffected skin is greater. This can sometimes increase social attention and emotional impact.<\/p>\n\n\n\n
EADV discussions on skin of colour, pigmentation, and treatment response are important because they highlight that vitiligo is not experienced in the same way by everyone. A small patch on the face, for example, may have a significant effect on confidence, identity, or cultural perception, even if it is medically limited in size.<\/p>\n\n\n\n
Skin type can also influence treatment choices and response. Dermatologists may need to consider risks such as post-inflammatory pigment changes, irritation, or uneven repigmentation, and ensure that advice on sun protection is clear and appropriate for all skin tones. EADV\u2019s international setting helps bring these perspectives together so care can be more inclusive, personalised, and realistic.<\/p>\n\n\n\n
Psychological Impact and Quality of Life<\/strong><\/h2>\n\n\n\nOne of the most important aspects of modern vitiligo care is its impact on quality of life. While vitiligo is not physically painful in most cases, it can have a significant emotional and psychological effect. Many people experience feelings such as self-consciousness, frustration, embarrassment, or exhaustion from repeatedly explaining their condition to others. These emotional responses can be just as important to address as the physical changes in skin appearance.<\/p>\n\n\n\n
\n- Emotional and Social Impact: <\/strong>Vitiligo can affect confidence and social comfort. Some individuals may feel hesitant in situations such as social gatherings, swimming, photography, dating, or professional environments due to concerns about appearance or attention.<\/li>\n\n\n\n
- Variation Between Individuals: <\/strong>The psychological impact of vitiligo is highly individual. Two people with the same level of skin involvement may experience it very differently, with one feeling unaffected and another experiencing significant emotional distress.<\/li>\n\n\n\n
- Importance of Patient Experience in Care: <\/strong>Modern dermatology emphasises patient-reported outcomes rather than focusing only on visible skin involvement. Understanding how vitiligo affects daily life helps clinicians provide more meaningful and personalised care.<\/li>\n\n\n\n
- Influence on Treatment Planning and Support: <\/strong>A patient\u2019s emotional wellbeing can influence treatment decisions, follow-up schedules, and support options. In some cases, psychological support or counselling may be an important part of overall management.<\/li>\n<\/ul>\n\n\n\n
Vitiligo care is not only about treating skin changes but also about understanding the emotional and social impact of the condition. Conferences and EADV discussions continue to reinforce the importance of quality of life in clinical decision-making. This approach helps dermatologists look beyond patch size and focus on how the condition affects each individual person. Ultimately, effective care should combine medical treatment with empathy, support, and attention to psychological wellbeing.<\/p>\n\n\n\n
Measuring Treatment Success<\/strong><\/h2>\n\n\n\nVitiligo treatment success is not always easy to define. Unlike some conditions where improvement is obvious, vitiligo often changes gradually and unevenly across different areas of the body, which can make progress harder to judge.<\/p>\n\n\n\n
Repigmentation may begin as small pigment spots around hair follicles, and it may appear earlier on the face compared with areas such as the hands or feet. Some areas may respond well to treatment while others show minimal change, even within the same person.<\/p>\n\n\n\n
EADV sessions often focus on how to measure outcomes more consistently, using tools such as clinical scoring systems, serial photographs, patient feedback, disease stability assessment, and quality-of-life measures. This helps create a clearer and more structured understanding of whether a treatment is truly working.<\/p>\n\n\n\n
For patients, this is important because unclear expectations can be frustrating. If you are simply told to \u201ccontinue treatment and wait,\u201d it may not be obvious what improvement should look like or when a change in approach should be considered. Better measurement supports clearer communication and more informed decisions between patients and clinicians, while also improving the quality and comparability of research studies.<\/p>\n\n\n\n
Combination Treatment Approaches<\/strong><\/h2>\n\n\n\nVitiligo treatment is often not based on a single long-term option, but rather on a combination of therapies tailored to the individual. Dermatologists may adjust treatment strategies depending on disease activity, response over time, and the areas of skin involved. This flexible approach allows care to be adapted rather than fixed, which is particularly important in a condition that can behave unpredictably. EADV sessions frequently explore how these combinations can be used effectively in real clinical practice.<\/p>\n\n\n\n
\n- Using Topical and Light-Based Therapies Together: <\/strong>A common approach involves combining topical treatments with phototherapy. Light-based therapy may help stimulate pigment production, while topical treatments can help reduce inflammation and support repigmentation.<\/li>\n\n\n\n
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n
- Balancing Benefits and Practical Challenges: <\/strong>While combination therapy can be effective, it also needs careful planning. More treatments do not always mean better results and may increase cost, side effects, or daily treatment burden for the patient.<\/li>\n\n\n\n
- Personalised Treatment Selection: <\/strong>The most effective combination is not necessarily the most intensive one. It is the approach that best fits the patient\u2019s condition, lifestyle, safety considerations, and personal treatment goals.<\/li>\n<\/ul>\n\n\n\n
Combination treatment approaches in vitiligo care highlight the importance of flexibility and personalisation in dermatology. EADV discussions continue to show that thoughtful pairing of therapies can improve outcomes when used appropriately. However, careful planning is essential to avoid unnecessary complexity or treatment burden. Ultimately, the best care is tailored to the individual, balancing effectiveness, safety, and long-term manageability.<\/p>\n\n\n\n
How EADV Sessions Influence Clinical Practice<\/strong><\/h2>\n\n\n\nEADV congress sessions do not usually change clinical practice overnight, but they do play an important role in shaping how dermatologists think, discuss, and refine patient care. A clinician may attend a session on new research and later apply that learning when reviewing treatment plans, advising patients, or deciding when specialist referral is needed.<\/p>\n\n\n\n
These sessions influence practice in several ways. They highlight emerging treatments, clarify where evidence is strong, and identify areas where more research is still needed. They also encourage doctors to focus more on patient experience and quality of life, not just clinical trial results.<\/p>\n\n\n\n
Over time, this collective learning can influence guidelines, prescribing patterns, medical education, and how clinicians communicate with patients. For example, if research consistently highlights the importance of early treatment in active vitiligo, clinicians may become more attentive to early signs of progression and intervene sooner.<\/p>\n\n\n\n
This is how conference evidence gradually translates into real-world care. It moves from presentations and discussions at EADV into everyday consultations, helping improve both medical decision-making and patient understanding.<\/p>\n\n\n\n
What Patients Can Take from EADV Vitiligo Discussions<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nIf you are living with vitiligo, you do not need to follow every scientific detail presented at EADV. However, it can be helpful to understand the general direction that modern care is taking.<\/p>\n\n\n\n
Vitiligo treatment is becoming more personalised, with greater focus on immune mechanisms, disease activity, timing of intervention, quality of life, and long-term management rather than short-term cosmetic change alone.<\/p>\n\n\n\n
At the same time, newer targeted treatments are emerging, but this does not mean older approaches have become irrelevant. Topical treatments, phototherapy, psychological support, camouflage techniques, and lifestyle guidance still play an important role depending on the individual\u2019s needs and condition.<\/p>\n\n\n\n
It is also important to be cautious with online information, as vitiligo can be emotionally challenging and may attract exaggerated claims or unrealistic promises. EADV discussions are valuable because they are based on scientific evidence, clinical experience, and peer-reviewed research rather than anecdotal reports or marketing claims.<\/p>\n\n\n\n
Future Directions in Vitiligo Research<\/strong><\/h2>\n\n\n\nThe future of vitiligo research is likely to focus on more targeted, personalised, and measurable treatment approaches. Researchers are continuing to explore immune pathways, genetic influences, biomarkers, relapse prevention, maintenance strategies, and combination therapies. Recent reviews summarising advances between 2020 and 2025 show how active and rapidly evolving this field has become.<\/p>\n\n\n\n
However, not every new development will automatically become standard care. Some treatments may require more long-term safety data, while others may only be effective in specific patient groups. Practical factors such as access, cost, and availability will also influence how widely new therapies are used in real-world settings.<\/p>\n\n\n\n
Despite these challenges, the overall direction is encouraging. Vitiligo is receiving significantly more scientific attention than in the past, and there is a stronger focus on patient-reported outcomes, quality of life, and shared decision-making alongside clinical results.<\/p>\n\n\n\n
EADV sessions play an important role in bringing these elements together. They provide a platform where scientific research, clinical experience, and patient perspectives can be discussed and refined, helping shape the future direction of vitiligo care.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n1. What is the main focus of EADV vitiligo sessions?
<\/strong>EADV vitiligo sessions focus on advancing understanding of Vitiligo through research updates, clinical guidelines, treatment innovations, and real-world patient care strategies.<\/p>\n\n\n\n2. Why is vitiligo discussed at European Academy of Dermatology and Venereology meetings?
<\/strong>Because vitiligo is a complex immune-mediated condition, EADV brings together experts to share evidence, improve treatment approaches, and address both medical and psychological aspects of care.<\/p>\n\n\n\n3. What new treatments are discussed in EADV vitiligo sessions?
<\/strong>Sessions often cover topical therapies, phototherapy, and newer targeted treatments such as JAK pathway-based approaches, including discussion of JAK inhibitors.<\/p>\n\n\n\n4. Do EADV sessions focus only on medical treatments?
<\/strong>No. They also focus on psychological impact, quality of life, disease classification, patient experience, and long-term management strategies for vitiligo.<\/p>\n\n\n\n5. How is vitiligo classified in EADV discussions?
<\/strong>Dermatologists discuss whether vitiligo is segmental or non-segmental, stable or active, and how different patterns affect treatment response and outcomes.<\/p>\n\n\n\n6. What role does phototherapy play in vitiligo treatment?
<\/strong>Phototherapy, especially narrowband UVB, remains an important treatment option and is often combined with topical or newer therapies to improve repigmentation.<\/p>\n\n\n\n7. Are JAK inhibitors a cure for vitiligo?
<\/strong>No. JAK inhibitors are promising targeted therapies that may help repigmentation, but they are not a cure and require more long-term safety and effectiveness data.<\/p>\n\n\n\n8. How do EADV sessions address psychological impact?
<\/strong>They highlight that vitiligo can significantly affect confidence, social life, and emotional wellbeing, and encourage integrating psychological support into treatment planning.<\/p>\n\n\n\n9. Do all patients respond the same way to vitiligo treatments?
<\/strong>No. Treatment response varies depending on skin type, disease activity, location of patches, and individual immune response, which is why personalised care is emphasised.<\/p>\n\n\n\n10. What is the future direction of vitiligo research discussed at EADV?
<\/strong>Future research focuses on targeted therapies, immune pathways, relapse prevention, combination treatments, and improving long-term outcomes while prioritising patient quality of life.<\/p>\n\n\n\nFinal Thoughts: The Evolving Understanding of Vitiligo Care at EADV<\/strong><\/h2>\n\n\n\nEADV vitiligo sessions highlight how rapidly this field is evolving, moving beyond simple repigmentation approaches towards a more complete understanding of Vitiligo as an immune-mediated condition. These discussions bring together new research, emerging therapies such as targeted treatments, and long-standing approaches like topical therapy and phototherapy, while also placing strong emphasis on quality of life, psychological wellbeing, and personalised care.<\/p>\n\n\n\n
The overall direction is clear: vitiligo management is becoming more individualised, evidence-driven, and focused on long-term outcomes rather than short-term results alone. If you\u2019re looking for Vitiligo treatment in London<\/a>, you can reach out to us at the London Dermatology Centre to book a consultation with one of our specialists.<\/p>\n\n\n\nReferences:<\/strong><\/h2>\n\n\n\n1. Shuaib, L. et al., 2025. Efficacy of Janus kinase inhibitor combined with phototherapy in non\u2011segmental vitiligo: systematic review and meta\u2011analysis. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12777791\/<\/a><\/p>\n\n\n\n2. 308\u202fnm excimer laser combined with JAK inhibitors for adult localized non\u2011segmental vitiligo: a multicenter randomized controlled trial. https:\/\/pubmed.ncbi.nlm.nih.gov\/40682379\/<\/a><\/p>\n\n\n\n3. Zhou, B. et al., 2024. Combination therapy with baricitinib and narrowband ultraviolet B for active non\u2011segmental vitiligo: a retrospective controlled study. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11668684\/<\/a><\/p>\n\n\n\n4. Mumford, J. et al., 2023. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB\u2011UVB phototherapy. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10015970\/<\/a><\/p>\n\n\n\n5. Combination therapy with 308\u2011nm excimer laser, topical tacrolimus, and short\u2011term systemic corticosteroids for segmental vitiligo. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0190962215015108<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such […]<\/p>\n","protected":false},"author":4,"featured_media":6013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"Uncategorized<\/a>","rttpg_excerpt":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such…","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6049,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6013"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Vitiligo care is not only about treating skin changes but also about understanding the emotional and social impact of the condition. Conferences and EADV discussions continue to reinforce the importance of quality of life in clinical decision-making. This approach helps dermatologists look beyond patch size and focus on how the condition affects each individual person. Ultimately, effective care should combine medical treatment with empathy, support, and attention to psychological wellbeing.<\/p>\n\n\n\n
Measuring Treatment Success<\/strong><\/h2>\n\n\n\nVitiligo treatment success is not always easy to define. Unlike some conditions where improvement is obvious, vitiligo often changes gradually and unevenly across different areas of the body, which can make progress harder to judge.<\/p>\n\n\n\n
Repigmentation may begin as small pigment spots around hair follicles, and it may appear earlier on the face compared with areas such as the hands or feet. Some areas may respond well to treatment while others show minimal change, even within the same person.<\/p>\n\n\n\n
EADV sessions often focus on how to measure outcomes more consistently, using tools such as clinical scoring systems, serial photographs, patient feedback, disease stability assessment, and quality-of-life measures. This helps create a clearer and more structured understanding of whether a treatment is truly working.<\/p>\n\n\n\n
For patients, this is important because unclear expectations can be frustrating. If you are simply told to \u201ccontinue treatment and wait,\u201d it may not be obvious what improvement should look like or when a change in approach should be considered. Better measurement supports clearer communication and more informed decisions between patients and clinicians, while also improving the quality and comparability of research studies.<\/p>\n\n\n\n
Combination Treatment Approaches<\/strong><\/h2>\n\n\n\nVitiligo treatment is often not based on a single long-term option, but rather on a combination of therapies tailored to the individual. Dermatologists may adjust treatment strategies depending on disease activity, response over time, and the areas of skin involved. This flexible approach allows care to be adapted rather than fixed, which is particularly important in a condition that can behave unpredictably. EADV sessions frequently explore how these combinations can be used effectively in real clinical practice.<\/p>\n\n\n\n
\n- Using Topical and Light-Based Therapies Together: <\/strong>A common approach involves combining topical treatments with phototherapy. Light-based therapy may help stimulate pigment production, while topical treatments can help reduce inflammation and support repigmentation.<\/li>\n\n\n\n
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n
- Balancing Benefits and Practical Challenges: <\/strong>While combination therapy can be effective, it also needs careful planning. More treatments do not always mean better results and may increase cost, side effects, or daily treatment burden for the patient.<\/li>\n\n\n\n
- Personalised Treatment Selection: <\/strong>The most effective combination is not necessarily the most intensive one. It is the approach that best fits the patient\u2019s condition, lifestyle, safety considerations, and personal treatment goals.<\/li>\n<\/ul>\n\n\n\n
Combination treatment approaches in vitiligo care highlight the importance of flexibility and personalisation in dermatology. EADV discussions continue to show that thoughtful pairing of therapies can improve outcomes when used appropriately. However, careful planning is essential to avoid unnecessary complexity or treatment burden. Ultimately, the best care is tailored to the individual, balancing effectiveness, safety, and long-term manageability.<\/p>\n\n\n\n
How EADV Sessions Influence Clinical Practice<\/strong><\/h2>\n\n\n\nEADV congress sessions do not usually change clinical practice overnight, but they do play an important role in shaping how dermatologists think, discuss, and refine patient care. A clinician may attend a session on new research and later apply that learning when reviewing treatment plans, advising patients, or deciding when specialist referral is needed.<\/p>\n\n\n\n
These sessions influence practice in several ways. They highlight emerging treatments, clarify where evidence is strong, and identify areas where more research is still needed. They also encourage doctors to focus more on patient experience and quality of life, not just clinical trial results.<\/p>\n\n\n\n
Over time, this collective learning can influence guidelines, prescribing patterns, medical education, and how clinicians communicate with patients. For example, if research consistently highlights the importance of early treatment in active vitiligo, clinicians may become more attentive to early signs of progression and intervene sooner.<\/p>\n\n\n\n
This is how conference evidence gradually translates into real-world care. It moves from presentations and discussions at EADV into everyday consultations, helping improve both medical decision-making and patient understanding.<\/p>\n\n\n\n
What Patients Can Take from EADV Vitiligo Discussions<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\nIf you are living with vitiligo, you do not need to follow every scientific detail presented at EADV. However, it can be helpful to understand the general direction that modern care is taking.<\/p>\n\n\n\n
Vitiligo treatment is becoming more personalised, with greater focus on immune mechanisms, disease activity, timing of intervention, quality of life, and long-term management rather than short-term cosmetic change alone.<\/p>\n\n\n\n
At the same time, newer targeted treatments are emerging, but this does not mean older approaches have become irrelevant. Topical treatments, phototherapy, psychological support, camouflage techniques, and lifestyle guidance still play an important role depending on the individual\u2019s needs and condition.<\/p>\n\n\n\n
It is also important to be cautious with online information, as vitiligo can be emotionally challenging and may attract exaggerated claims or unrealistic promises. EADV discussions are valuable because they are based on scientific evidence, clinical experience, and peer-reviewed research rather than anecdotal reports or marketing claims.<\/p>\n\n\n\n
Future Directions in Vitiligo Research<\/strong><\/h2>\n\n\n\nThe future of vitiligo research is likely to focus on more targeted, personalised, and measurable treatment approaches. Researchers are continuing to explore immune pathways, genetic influences, biomarkers, relapse prevention, maintenance strategies, and combination therapies. Recent reviews summarising advances between 2020 and 2025 show how active and rapidly evolving this field has become.<\/p>\n\n\n\n
However, not every new development will automatically become standard care. Some treatments may require more long-term safety data, while others may only be effective in specific patient groups. Practical factors such as access, cost, and availability will also influence how widely new therapies are used in real-world settings.<\/p>\n\n\n\n
Despite these challenges, the overall direction is encouraging. Vitiligo is receiving significantly more scientific attention than in the past, and there is a stronger focus on patient-reported outcomes, quality of life, and shared decision-making alongside clinical results.<\/p>\n\n\n\n
EADV sessions play an important role in bringing these elements together. They provide a platform where scientific research, clinical experience, and patient perspectives can be discussed and refined, helping shape the future direction of vitiligo care.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n1. What is the main focus of EADV vitiligo sessions?
<\/strong>EADV vitiligo sessions focus on advancing understanding of Vitiligo through research updates, clinical guidelines, treatment innovations, and real-world patient care strategies.<\/p>\n\n\n\n2. Why is vitiligo discussed at European Academy of Dermatology and Venereology meetings?
<\/strong>Because vitiligo is a complex immune-mediated condition, EADV brings together experts to share evidence, improve treatment approaches, and address both medical and psychological aspects of care.<\/p>\n\n\n\n3. What new treatments are discussed in EADV vitiligo sessions?
<\/strong>Sessions often cover topical therapies, phototherapy, and newer targeted treatments such as JAK pathway-based approaches, including discussion of JAK inhibitors.<\/p>\n\n\n\n4. Do EADV sessions focus only on medical treatments?
<\/strong>No. They also focus on psychological impact, quality of life, disease classification, patient experience, and long-term management strategies for vitiligo.<\/p>\n\n\n\n5. How is vitiligo classified in EADV discussions?
<\/strong>Dermatologists discuss whether vitiligo is segmental or non-segmental, stable or active, and how different patterns affect treatment response and outcomes.<\/p>\n\n\n\n6. What role does phototherapy play in vitiligo treatment?
<\/strong>Phototherapy, especially narrowband UVB, remains an important treatment option and is often combined with topical or newer therapies to improve repigmentation.<\/p>\n\n\n\n7. Are JAK inhibitors a cure for vitiligo?
<\/strong>No. JAK inhibitors are promising targeted therapies that may help repigmentation, but they are not a cure and require more long-term safety and effectiveness data.<\/p>\n\n\n\n8. How do EADV sessions address psychological impact?
<\/strong>They highlight that vitiligo can significantly affect confidence, social life, and emotional wellbeing, and encourage integrating psychological support into treatment planning.<\/p>\n\n\n\n9. Do all patients respond the same way to vitiligo treatments?
<\/strong>No. Treatment response varies depending on skin type, disease activity, location of patches, and individual immune response, which is why personalised care is emphasised.<\/p>\n\n\n\n10. What is the future direction of vitiligo research discussed at EADV?
<\/strong>Future research focuses on targeted therapies, immune pathways, relapse prevention, combination treatments, and improving long-term outcomes while prioritising patient quality of life.<\/p>\n\n\n\nFinal Thoughts: The Evolving Understanding of Vitiligo Care at EADV<\/strong><\/h2>\n\n\n\nEADV vitiligo sessions highlight how rapidly this field is evolving, moving beyond simple repigmentation approaches towards a more complete understanding of Vitiligo as an immune-mediated condition. These discussions bring together new research, emerging therapies such as targeted treatments, and long-standing approaches like topical therapy and phototherapy, while also placing strong emphasis on quality of life, psychological wellbeing, and personalised care.<\/p>\n\n\n\n
The overall direction is clear: vitiligo management is becoming more individualised, evidence-driven, and focused on long-term outcomes rather than short-term results alone. If you\u2019re looking for Vitiligo treatment in London<\/a>, you can reach out to us at the London Dermatology Centre to book a consultation with one of our specialists.<\/p>\n\n\n\nReferences:<\/strong><\/h2>\n\n\n\n1. Shuaib, L. et al., 2025. Efficacy of Janus kinase inhibitor combined with phototherapy in non\u2011segmental vitiligo: systematic review and meta\u2011analysis. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12777791\/<\/a><\/p>\n\n\n\n2. 308\u202fnm excimer laser combined with JAK inhibitors for adult localized non\u2011segmental vitiligo: a multicenter randomized controlled trial. https:\/\/pubmed.ncbi.nlm.nih.gov\/40682379\/<\/a><\/p>\n\n\n\n3. Zhou, B. et al., 2024. Combination therapy with baricitinib and narrowband ultraviolet B for active non\u2011segmental vitiligo: a retrospective controlled study. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11668684\/<\/a><\/p>\n\n\n\n4. Mumford, J. et al., 2023. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB\u2011UVB phototherapy. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10015970\/<\/a><\/p>\n\n\n\n5. Combination therapy with 308\u2011nm excimer laser, topical tacrolimus, and short\u2011term systemic corticosteroids for segmental vitiligo. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0190962215015108<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such […]<\/p>\n","protected":false},"author":4,"featured_media":6013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"Uncategorized<\/a>","rttpg_excerpt":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such…","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6049,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6013"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Vitiligo treatment is often not based on a single long-term option, but rather on a combination of therapies tailored to the individual. Dermatologists may adjust treatment strategies depending on disease activity, response over time, and the areas of skin involved. This flexible approach allows care to be adapted rather than fixed, which is particularly important in a condition that can behave unpredictably. EADV sessions frequently explore how these combinations can be used effectively in real clinical practice.<\/p>\n\n\n\n
- \n
- Using Topical and Light-Based Therapies Together: <\/strong>A common approach involves combining topical treatments with phototherapy. Light-based therapy may help stimulate pigment production, while topical treatments can help reduce inflammation and support repigmentation.<\/li>\n\n\n\n
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n
- Balancing Benefits and Practical Challenges: <\/strong>While combination therapy can be effective, it also needs careful planning. More treatments do not always mean better results and may increase cost, side effects, or daily treatment burden for the patient.<\/li>\n\n\n\n
- Personalised Treatment Selection: <\/strong>The most effective combination is not necessarily the most intensive one. It is the approach that best fits the patient\u2019s condition, lifestyle, safety considerations, and personal treatment goals.<\/li>\n<\/ul>\n\n\n\n
Combination treatment approaches in vitiligo care highlight the importance of flexibility and personalisation in dermatology. EADV discussions continue to show that thoughtful pairing of therapies can improve outcomes when used appropriately. However, careful planning is essential to avoid unnecessary complexity or treatment burden. Ultimately, the best care is tailored to the individual, balancing effectiveness, safety, and long-term manageability.<\/p>\n\n\n\n
How EADV Sessions Influence Clinical Practice<\/strong><\/h2>\n\n\n\n
EADV congress sessions do not usually change clinical practice overnight, but they do play an important role in shaping how dermatologists think, discuss, and refine patient care. A clinician may attend a session on new research and later apply that learning when reviewing treatment plans, advising patients, or deciding when specialist referral is needed.<\/p>\n\n\n\n
These sessions influence practice in several ways. They highlight emerging treatments, clarify where evidence is strong, and identify areas where more research is still needed. They also encourage doctors to focus more on patient experience and quality of life, not just clinical trial results.<\/p>\n\n\n\n
Over time, this collective learning can influence guidelines, prescribing patterns, medical education, and how clinicians communicate with patients. For example, if research consistently highlights the importance of early treatment in active vitiligo, clinicians may become more attentive to early signs of progression and intervene sooner.<\/p>\n\n\n\n
This is how conference evidence gradually translates into real-world care. It moves from presentations and discussions at EADV into everyday consultations, helping improve both medical decision-making and patient understanding.<\/p>\n\n\n\n
What Patients Can Take from EADV Vitiligo Discussions<\/strong><\/h2>\n\n\n\n
<\/figure>\n\n\n\nIf you are living with vitiligo, you do not need to follow every scientific detail presented at EADV. However, it can be helpful to understand the general direction that modern care is taking.<\/p>\n\n\n\n
Vitiligo treatment is becoming more personalised, with greater focus on immune mechanisms, disease activity, timing of intervention, quality of life, and long-term management rather than short-term cosmetic change alone.<\/p>\n\n\n\n
At the same time, newer targeted treatments are emerging, but this does not mean older approaches have become irrelevant. Topical treatments, phototherapy, psychological support, camouflage techniques, and lifestyle guidance still play an important role depending on the individual\u2019s needs and condition.<\/p>\n\n\n\n
It is also important to be cautious with online information, as vitiligo can be emotionally challenging and may attract exaggerated claims or unrealistic promises. EADV discussions are valuable because they are based on scientific evidence, clinical experience, and peer-reviewed research rather than anecdotal reports or marketing claims.<\/p>\n\n\n\n
Future Directions in Vitiligo Research<\/strong><\/h2>\n\n\n\n
The future of vitiligo research is likely to focus on more targeted, personalised, and measurable treatment approaches. Researchers are continuing to explore immune pathways, genetic influences, biomarkers, relapse prevention, maintenance strategies, and combination therapies. Recent reviews summarising advances between 2020 and 2025 show how active and rapidly evolving this field has become.<\/p>\n\n\n\n
However, not every new development will automatically become standard care. Some treatments may require more long-term safety data, while others may only be effective in specific patient groups. Practical factors such as access, cost, and availability will also influence how widely new therapies are used in real-world settings.<\/p>\n\n\n\n
Despite these challenges, the overall direction is encouraging. Vitiligo is receiving significantly more scientific attention than in the past, and there is a stronger focus on patient-reported outcomes, quality of life, and shared decision-making alongside clinical results.<\/p>\n\n\n\n
EADV sessions play an important role in bringing these elements together. They provide a platform where scientific research, clinical experience, and patient perspectives can be discussed and refined, helping shape the future direction of vitiligo care.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n
1. What is the main focus of EADV vitiligo sessions?
<\/strong>EADV vitiligo sessions focus on advancing understanding of Vitiligo through research updates, clinical guidelines, treatment innovations, and real-world patient care strategies.<\/p>\n\n\n\n2. Why is vitiligo discussed at European Academy of Dermatology and Venereology meetings?
<\/strong>Because vitiligo is a complex immune-mediated condition, EADV brings together experts to share evidence, improve treatment approaches, and address both medical and psychological aspects of care.<\/p>\n\n\n\n3. What new treatments are discussed in EADV vitiligo sessions?
<\/strong>Sessions often cover topical therapies, phototherapy, and newer targeted treatments such as JAK pathway-based approaches, including discussion of JAK inhibitors.<\/p>\n\n\n\n4. Do EADV sessions focus only on medical treatments?
<\/strong>No. They also focus on psychological impact, quality of life, disease classification, patient experience, and long-term management strategies for vitiligo.<\/p>\n\n\n\n5. How is vitiligo classified in EADV discussions?
<\/strong>Dermatologists discuss whether vitiligo is segmental or non-segmental, stable or active, and how different patterns affect treatment response and outcomes.<\/p>\n\n\n\n6. What role does phototherapy play in vitiligo treatment?
<\/strong>Phototherapy, especially narrowband UVB, remains an important treatment option and is often combined with topical or newer therapies to improve repigmentation.<\/p>\n\n\n\n7. Are JAK inhibitors a cure for vitiligo?
<\/strong>No. JAK inhibitors are promising targeted therapies that may help repigmentation, but they are not a cure and require more long-term safety and effectiveness data.<\/p>\n\n\n\n8. How do EADV sessions address psychological impact?
<\/strong>They highlight that vitiligo can significantly affect confidence, social life, and emotional wellbeing, and encourage integrating psychological support into treatment planning.<\/p>\n\n\n\n9. Do all patients respond the same way to vitiligo treatments?
<\/strong>No. Treatment response varies depending on skin type, disease activity, location of patches, and individual immune response, which is why personalised care is emphasised.<\/p>\n\n\n\n10. What is the future direction of vitiligo research discussed at EADV?
<\/strong>Future research focuses on targeted therapies, immune pathways, relapse prevention, combination treatments, and improving long-term outcomes while prioritising patient quality of life.<\/p>\n\n\n\nFinal Thoughts: The Evolving Understanding of Vitiligo Care at EADV<\/strong><\/h2>\n\n\n\n
EADV vitiligo sessions highlight how rapidly this field is evolving, moving beyond simple repigmentation approaches towards a more complete understanding of Vitiligo as an immune-mediated condition. These discussions bring together new research, emerging therapies such as targeted treatments, and long-standing approaches like topical therapy and phototherapy, while also placing strong emphasis on quality of life, psychological wellbeing, and personalised care.<\/p>\n\n\n\n
The overall direction is clear: vitiligo management is becoming more individualised, evidence-driven, and focused on long-term outcomes rather than short-term results alone. If you\u2019re looking for Vitiligo treatment in London<\/a>, you can reach out to us at the London Dermatology Centre to book a consultation with one of our specialists.<\/p>\n\n\n\n
References:<\/strong><\/h2>\n\n\n\n
1. Shuaib, L. et al., 2025. Efficacy of Janus kinase inhibitor combined with phototherapy in non\u2011segmental vitiligo: systematic review and meta\u2011analysis. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12777791\/<\/a><\/p>\n\n\n\n
2. 308\u202fnm excimer laser combined with JAK inhibitors for adult localized non\u2011segmental vitiligo: a multicenter randomized controlled trial. https:\/\/pubmed.ncbi.nlm.nih.gov\/40682379\/<\/a><\/p>\n\n\n\n
3. Zhou, B. et al., 2024. Combination therapy with baricitinib and narrowband ultraviolet B for active non\u2011segmental vitiligo: a retrospective controlled study. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11668684\/<\/a><\/p>\n\n\n\n
4. Mumford, J. et al., 2023. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB\u2011UVB phototherapy. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10015970\/<\/a><\/p>\n\n\n\n
5. Combination therapy with 308\u2011nm excimer laser, topical tacrolimus, and short\u2011term systemic corticosteroids for segmental vitiligo. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0190962215015108<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such […]<\/p>\n","protected":false},"author":4,"featured_media":6013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/05\/imagess-4-2-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"Uncategorized<\/a>","rttpg_excerpt":"Vitiligo is often described as a skin pigmentation condition, but anyone who has lived with it knows it is much more than a change in skin colour. It can affect confidence, daily comfort, social interactions, treatment decisions, and the way you feel when you look in the mirror. That is why international dermatology meetings such…","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6049,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6013"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
- Sequential and Maintenance Strategies: <\/strong>Some patients may start with active treatment and later move into maintenance therapy to preserve results. This can include ongoing topical applications or reduced-frequency phototherapy depending on response.<\/li>\n\n\n\n